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PROGNOSTIC SIGNIFICANCE OF SERUM URIC ACID LEVELS IN 
CONGESTIVE CARDIAC FAILURE AND ITS CORRELATION WITH 
EJECTION FRACTION   
ABSTRACT 
OBJECTIVE: 
The  aim of the study is to access the prognostic significance of serum uric acid 
levels in patients with congestive cardiac failure and its correlation with ejection 
fraction. 
MATERIALS AND METHODS: 
This study was performed in Department of Medicine, Coimbatore Medical 
College hospital, Coimbatore. Serum uric acid levels were measured in 100 heart 
failure patients and their levels were correlated with ejection fraction and NYHA 
functional class for heart failure. Hemodynamic characteristics and risk factors of 
the patients were also assessed. Patients were followed up for 30 days with end 
points of cardiac death or rehospitalisation. 
RESULTS: 
Out of 100 patients analysed, 73 patients had higher uric acid levels and 27 had 
normal uric acid levels. Serum uric acid levels correlated negatively with ejection 
fraction and positively with NYHA functional class, thus predicting the prognosis 
and severity in heart failure patients. Patients with higher uric acid levels were in 
severe heart failure and required significantly more rehospitalisation and had more 
deaths compared to those with normal uric acid levels. 
CONCLUSION: 
Higher serum uric acid levels is a prognostic predictor in patients with congestive 
cardiac failure. Monitoring of serum uric acid levels may be useful for the 
management of patients with congestive cardiac failure. 
Key Words : Uric acid, Congestive cardiac failure, Ejection fraction, Prognosis. 
 
INTRODUCTION 
Congestive heart failure (CHF) is an important cause for morbidity 
and mortality irrespective of age and sex across the globe. The prevalence of heart 
failure has significantly increased over the past decade and it is the leading cause 
of hospitalization in developed and developing countries. This includes patients 
presenting with new onset heart failure and as well as with worsening of            
pre- existing chronic heart failure. Heart failure is associated with poor prognosis 
leading to frequent hospitalizations, poor quality of life and shortened life span. 
Hence it is important to identify simple and effective investigatory modalities for 
early diagnosis, risk stratification and prognosis. 
Uric acid (UA) is a metabolic end product of purine metabolism. Uric 
acid, an important antioxidant in plasma acts as a free radical when in excess. Uric 
acid appears to play a pathological role in the development of hypertension, 
diabetes, obesity and metabolic syndrome contributing to cardiovascular mortality. 
Excess uric acid levels results in endothelial dysfunction, increased RAAS (Renin 
Angiotensin Aldosterone System) activation and vascular smooth muscle 
proliferation leading to cardiovascular and renal diseases.1 
   Serum uric acid levels are increased in CHF mostly by increased 
generation and partly by reduced excretion or both. Elevated uric acid levels 
indicate cardiac dysfunction and progression of heart failure through oxidative 
stress and free radical injury by increased xanthine oxidase activity.2 
Epidemiological studies have shown that increased uric acid levels 
serve as a valid prognostic marker in congestive heart failure and indicate 
metabolic, functional and hemodynamic derangements. The purpose of this study 
is to determine the association between uric acid levels and heart failure and to find 
its significance in predicting mortality and severity of the disease as a prognostic 
risk marker. 
 
 
  
  
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
  
AIMS AND OBJECTIVES 
Aim:  
The aim of the study is to determine the prognostic significance of 
serum uric acid levels in patients with congestive cardiac failure and its correlation 
with ejection fraction. 
Objectives:  
1. To validate increase in serum uric acid levels in congestive heart failure. 
2. To correlate serum uric acid levels with ejection fraction. 
3. To establish the relationship of increased uric acid levels to functional class 
(NYHA New York Heart Association) in congestive heart failure in predicting    
the severity. 
4. To determine the association of serum uric acid levels to the individual risk 
factors in patients with congestive heart failure.  
5. To determine the prognosis in terms of 30 day mortality rate in congestive heart 
failure patients with high uric acid levels. 
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REVIEW OF LITERATURE 
HEART FAILURE 
Definition: 
   Heart failure (HF) is a complex clinical syndrome due to inherited or 
acquired abnormality of cardiac structural or functional impairment in ventricular 
filling or ejection of blood, resulting in a constellation of clinical symptoms and 
signs, frequent hospitalizations, a poor quality of life and a shortened life 
expectancy.3 
Epidemiology:  
Heart failure is a global problem affecting more than 20 million 
people.5 The incidence and prevalence of heart failure has been on the increasing 
trend in the last 30 years due to increase in the lifespan.4 The disease increases with 
age affecting 6-10% of people over the age of 65. Annually 0.5 to 1.8 million 
people are affected in India with estimated total prevalence of about 1.3 to 4.6 
million.6 The increasing prevalence of heart failure may be due to improved 
diagnostic and therapeutic techniques for common cardiac ailments. 
Despite tremendous advancements in the management of heart failure 
over the past decade, the morbidity and mortality in patients with heart failure 
remains on the higher side. In the western countries, heart failure is seen mostly in 
the elderly population. However, in India, the picture is quite different with 
relatively younger age group are affected more in comparison to western countries. 
Heart failure is usually associated with risk factors like  diabetes mellitus, 
hypertension, ischaemic heart disease, obesity and valvular heart disease.7,8 In 
India, the leading causes of heart failure are coronary artery disease, diabetes 
mellitus, hypertension, valvular heart disease and myocarditis. Compared to the 
western world, rheumatic heart disease is a more significant cause of heart failure 
in India.  
Classification of Heart Failure: 
Acute and chronic heart failure:  
Acute heart failure is defined as the structural and functional 
maladaptation of the heart, occurring in a very short interval of time, leading to 
rapid onset of clinical signs and symptoms, requiring emergency lifesaving 
support.9 It is characterized by sudden onset of severe symptoms requiring 
emergent treatment. The development of symptoms is usually preceded by a 
precipitating event. The precipitating factors may act on a previously normal heart 
in new onset Heart failure or in the already diseased heart, causing acute 
decompensation of chronic heart failure. The sudden shift of blood from the 
systemic circulation to the pulmonary circulation can lead to sudden onset of 
dyspnoea in the absence of peripheral edema.  
Chronic heart failure refers to a comparatively stable state 
characterized by persistent but frequently stable symptoms on and off, requiring 
indefinite treatment also known as compensated heart failure. The progression of 
this state to acute decompensation occurs following a triggering factor. The 
precipitating factor may vary in individual patients. Fatigue is a very common 
symptom due to under perfusion of the skeletal muscles resulting in exercise 
intolerance. Accumulation of fluid may occur, resulting in pulmonary and 
peripheral congestion and anasarca described as congestive heart failure. However, 
in some patients heart failure may present in the absence of these congestive 
symptoms. So the term ‘congestive heart failure’ has been replaced by the term 
‘heart failure’.  
Systolic and diastolic heart failure:  
Systolic heart failure (the most common type) refers to a clinical 
syndrome characterized by impaired left ventricular contractility and decreased 
cardiac output. It presents with symptoms of fatigue, breathlessness and poor 
exercise tolerance. These patients are characterized by the presence of a large, 
dilated heart with significant systolic dysfunction.  
Diastolic dysfunction refers to patients in whom the left ventricular 
ejection fraction is normal or near normal at rest with normal sized heart. The 
pathophysiology responsible for diastolic heart failure is usually impaired diastolic 
filling of the ventricles with normal contractility and cardiac output. It may be 
accompanied by left ventricular hypertrophy.  
Left and right heart failure:  
In the absence of regurgitation, abnormal communications or shunts, 
both the right heart and left heart function like a circuit in series, contributes almost 
equal cardiac output. Hence either side cannot eject more blood than the other. The 
term left heart failure is used in the context of congestion and increased pressures 
in the pulmonary circulation. Right heart failure is used in patients presenting with 
signs and symptoms of congestion and increased pressures in the systemic 
circulation, manifesting as elevated jugular venous pressure and congestive liver, 
ascites and dependant edema. 
Current Classification:  
In patients with heart failure, the left ventricular functional 
abnormalities are usually variable. They may have a wide spectrum of left 
ventricular size and function. Both systolic and diastolic dysfunction may be seen 
in many patients with heart failure, irrespective of the ejection fraction. The most 
important factor in classifying patients with heart failure is the left ventricular 
ejection fraction, since the clinical features, risk factors, prognosis and response to 
therapy differs in patients with varying ejection fractions. Ejection fraction is an 
important determinant of left ventricular function and therefore heart failure 
patients are primarily classified into those with reduced ejection fraction and those 
with preserved ejection fraction. (Fig. 1)  
Heart failure with reduced ejection fraction (HFrEF):  
  Majority of the patients with reduced ejection fraction have varying 
degrees of enlargement of the left ventricles and decreased cardiac output. The cut-
off limit of ejection fraction for defining  has varied from ≤35%, <40% and ≤40% 
over the past few years.10-12 The current guidelines recommend an ejection fraction 
value of ≤40% for the diagnosis of reduced ejection fraction in the presence of 
signs and symptoms of heart failure commonly referred as systolic failure.U 
Heart failure with preserved ejection fraction (HFpEF):  
  Around 50% percentage of patients with heart failure who do not have 
reduced ejection fraction,13 but ventricle filling is impaired with normal or 
increased cardiac output. They are commonly referred as diastolic failure. Since 
some of the patients do not have an entirely normal ejection fraction, but also do 
not have a significant systolic dysfunction, the term preserved ejection fraction has 
been coined.  
  Patients with an ejection fraction of 40% to 50% are referred to as an 
intermediate group. Making a diagnosis of heart failure with preserved ejection 
fraction is challenging, since majority of them are non-cardiac causes. These 
patients usually belong to the elderly age group with history of hypertension, 
diabetes mellitus, obesity, dyslipidemia and arrhythmias.13,14 
  The most common cause of heart failure with preserved ejection 
fraction is hypertension.15 It has been found that some of the patients with 
preserved ejection fraction were previously classified under heart failure with 
reduced ejection fraction.16 Further studies are required to further characterize 
these patients, because these patients have a distinct clinical profile when 
compared to those with persistent reduced or preserved ejection fraction. No 
definite therapies are available for patients with preserved ejection fraction. 
 
 
 
 Fig.1. Classification of patients based on ejection fraction 
Severity of Heart Failure:  
  The severity of heart failure can be assessed by classifying the 
patients. Two classification systems are accepted worldwide.  
  The first one is a functional classification, the New York Heart 
Association (NYHA) classification. (Fig. 2) It provides information about the 
functional capacity and the exercise tolerance of the patient. Patients are classified 
into four classes. It is a very simple and easy method to estimate the cardiac 
function with symptoms alone.  
 
Fig 2. New York Heart Association (NYHA) classification of Heart Failure  
  The second staging is recommended by the American Heart 
Association (AHA) and American College of Cardiology Foundation (ACCF). 
(Fig. 3) It helps in assessing the development and progression of heart failure over 
a period of time. It analyses both the abnormalities in cardiac structure and the risk 
factors associated with heart failure. There are numerous etiologies for heart 
failure. (Fig. 4) 
 
Fig. 3. AHA/ACCF staging of Heart Failure 
 
                         Depressed Ejection Fraction (<40%) 
Coronary artery disease Nonischemic dilated cardiomyopathy 
 Myocardial infarctiona Familial/genetic disorders 
Myocardial ischemiaa Infiltrative disordersa 
Chronic pressure overload Toxic/drug-induced damage 
Hypertensiona Metabolic disordera  
Obstructive valvular diseasea Viral 
Chronic volume overload Chagas' disease 
Regurgitant valvular disease Disorders of rate and rhythm 
Intracardiac (left-to-right) shunting Chronic bradyarrhythmias 
Extracardiac shunting Chronic tachyarrhythmias 
Preserved Ejection Fraction (>40–50%)  
Pathologic hypertrophy Restrictive cardiomyopathy 
Primary (hypertrophic 
cardiomyopathies) 
Infiltrative disorders (amyloidosis, 
sarcoidosis) 
Secondary (hypertension) Storage diseases (hemochromatosis) 
 
Aging Fibrosis 
  Endomyocardial disorders 
Pulmonary Heart Disease  
Cor pulmonale   
Pulmonary vascular disorders   
High-Output States  
Metabolic disorders Excessive blood-flow requirements 
Thyrotoxicosis Systemic arteriovenous shunting 
Nutritional disorders (beriberi) Chronic anemia 
 
 
Note: a Indicates conditions that can also lead to heart failure with a preserved 
ejection fraction. 
Fig. 4. Etiologies of Heart Failure 
 
 
 
 
 
ACUTE HEART FAILURE SYNDROMES:  
Definition:  
  Acute heart failure syndromes (AHFS) is a broad term that 
encompasses a group of related disorders, which were previously known by 
various overlapping terms, including acute heart failure (AHF), acute 
decompensated heart failure (ADHF) and acute decompensation of chronic heart 
failure (ADCHF). AHFS is defined as new onset or recurrence of gradually or 
rapidly developing symptoms and signs of heart failure usually preceded by a 
precipitating factor, requiring urgent or emergent life saving therapy and resulting 
in hospitalization  
Classification: 
   The wide spectrum of AHFS does not allow a comprehensive 
classification. A lot of classification schemes have been tried, but none of them 
have been accepted universally. A simple approach to classify AHFS relies on the 
presence of previous history of heart failure symptoms and signs.9 Based on this, 
the patients can be simply classified into de novo (new onset) heart failure and 
worsening of chronic heart failure. (Fig. 5)  
 Fig. 5. Classification of Acute Heart Failure Syndromes  
De Novo Heart Failure:  
  Patients in this category develop symptoms and signs of heart failure 
for the first time in their life, without previous history of heart disease. They may 
or may not have cardiovascular risk factors like diabetes, hypertension or 
dyslipidemia. Acute myocarditis is an example for de novo AHFS without any 
prior risk factor. More often patients will have risk factors for heart disease with 
prior subtle symptoms like fatigue. 
 
Worsening chronic heart failure:  
  Majority (80%) of the patients with AHFS belong to this category. 
They have history of heart failure on a long term basis and present with symptoms 
of acute decompensation by a triggering factor. Some of the patients in this group 
suffer from advanced heart failure, refractory to available modalities of treatment, 
requiring cardiac transplantation. 
Causes and Precipitating Factors: 
  Patients with AHFS most often present with symptoms due to a 
precipitating factor. The various causes and precipitating factors are mentioned in 
Fig. 6.  
 Fig. 6. Causes and precipitating factors of Heart Failure  
Pathophysiology:  
  AHFS comprise a wide range of related disorders resulting in patients 
presenting with symptoms and signs of acute heart failure. The mechanisms 
leading to acute decompensation is highly varied and overlapping between 
patients. These mechanisms are involved in different patients with varying degrees 
of association. So, a single and simple conceptual model for explaining these 
pathogenetic mechanisms is not possible. The final common pathway of all these 
mechanisms leading to symptoms is the onset of pulmonary congestion due to 
increased left ventricular end diastolic pressure. The pathogenesis can be explained 
as a consequence of interplay between a pre-existing substrate and mechanisms 
that initiate and amplify the cardiac dysfunction. (Fig. 7)  
  The cardiac structure and function is the underlying normal substrate. 
The cardiac structure and function may be normal or abnormal. Patients with 
worsening chronic heart failure have an underlying compensated heart failure, 
which on interaction with initiating and amplifying factors lead to acute 
decompensation by altering the substrate function. The initiating factors may be 
extra cardiac or cardiac in origin. In patients with a normal substrate, the initiating 
mechanism must be strong enough to produce symptoms of decompensation, 
whereas in patients with abnormal substrate, minor precipitating factors are enough 
to cause decompensation. Irrespective of the substrate and initiating factors, 
various factors amplify the already initiated heart failure. These include 
inflammatory factors, oxidative stress, injury to the myocardium, neurohumoral 
factors and other non-cardiac factors like renal failure.17  
 
Fig. 7. Pathogenesis of Heart failure syndromes  
  The final end result in the pathogenesis of AHFS is the onset of 
pulmonary or systemic congestion, which is the hallmark of heart failure producing 
most of the symptoms.18 This congestion is mainly due to the raised left ventricular 
diastolic pressure in heart failure with reduced ejection fraction. Body weight has 
been found to be an important factor, which usually precedes the onset of CHF.19,20 
Congestion, in the initial phases may be asymptomatic, manifesting as 
hemodynamic congestion – elevated left ventricular filling pressures, which can be 
diagnosed and monitored by implantable hemodynamic devices. This 
hemodynamic congestion usually is followed by a phase of clinical congestion, 
which is manifested by fine end inspiratory basal crackles in the lung fields, 
elevated JVP and peripheral dependent edema.  
  Both cardiac and extracardiac mechanisms play an important role in 
the development of CHF. The impairment in cardiac functions is pivotal in 
understanding the pathogenesis. The dysfunction may be systolic or diastolic. 
Impaired pumping of blood from the heart, called systolic failure can trigger 
variety of adverse mechanisms known as ventricular remodeling, initially thought 
to be a compensatory phenomenon, at later stages of decompensation can amplify 
the heart failure.  
  The most significant mechanisms include the renin angiotensin 
aldosterone activating system (RAAS) and sympathetic nervous system. Decreased 
cardiac output leads to hypoperfusion of the kidneys and decreased distal delivery 
of sodium to distal convoluted tubules. By tubulo glomerular feed back, these 
mechanisms lead to vasoconstriction, retention of sodium and water, redistribution 
of fluid from the periphery and hence increase in left ventricular filling pressures 
leading to the clinical manifestations. Subsequent activation of neurohumoral 
mechanisms lead to remodeling of the ventricles and myocyte loss, which further 
decreases the systolic function ending up in a vicious cycle.(Fig. 8)  
  Sympathetic oveactivity leading to vasoconstriction and increased 
peripheral resistance leads to further augmentation of symptoms. Dysfunction of 
cardiac contractility is essential for the development of acute heart failure, however 
in about 50% of patients with AHFS have a substantially preserved ejection 
fraction.21,22 In these patients, there will be inefficient filling of the ventricles. 
Isolated diastolic insufficiency rarely leads to AHFS, but it can be a potential 
substrate for the initiating and amplifying mechanisms causing symptoms of acute 
decompensation.23  
 Fig. 8. Role of Neurohormones in the pathogenesis of CHF 
  
Clinical features:  
  The commonest presenting symptom of CHF is breathlessness, which 
may be at rest or on exertion depending upon the severity of the heart failure. 
Exertional dyspnoea, which is seen in 89% of patients with CHF, is due to the 
congestion in the pulmonary circulation and elevated left ventricular end diastolic 
pressure.24 Orthopnoea and paroxysmal nocturnal dyspnoea are more specific for 
left sided systolic failure.  
  In patients admitted with CHF, initial assessment gives reliable 
prognostic information about the patient. An important step in the assessment is the 
measurement of blood pressure, which defines the clinical spectrum that helps in 
defining the treatment protocol. Systolic blood pressure, diastolic blood pressure, 
pulse pressure and orthostatic blood pressure variability may give important 
information on the pathogenesis of CHF. Systolic pressure is determined by the 
cardiac output and diastolic pressure by the peripheral resistance, both of which are 
important determinants of cardiac contractility and ejection fraction. Most patients 
with CHF have a high or normal systolic blood pressure. A limited number of 
patients present with clinical hypotension, defined as systolic blood pressure less 
than 90mm Hg. In patients who have high systolic blood pressure on admission, 
the increase in blood pressure may be due to compensatory increased sympathetic 
system activation, which increases the tone of the blood vessels, leading to reactive 
hypertension. The systolic blood pressure in this group of patients may return back 
to normal after treatment is started, whereas some patients may be resistant to the 
initial treatment. Such patients may require treatment with arterial vasodilators.25  
  The increase in sympathetic tone may also lead to rise in diastolic 
blood pressure. However, a fall in the diastolic blood pressure indicates peripheral 
vasodilatation, which may be caused by high output states. An increase in pulse 
pressure may also be seen in high output states like aortic regurgitation, 
thyrotoxicosis and anaemia. A decrease in pulse pressure indicates a combination 
of low cardiac output and systemic vasoconstriction, which is a poor prognostic 
indicator with 2.5 times increase in mortality risk than with wide pulse pressure. 
  The general physical examination and assessment of the vital signs 
will indicate the volume status, the presence and severity of respiratory distress, 
oxygenation and signs of any other underlying systemic disorder. In all patients 
with acute decompensation of chronic heart failure, the underlying precipitating 
factor must be found out for effective treatment outcomes. The presence of altered 
higher mental functions indicates hypoperfusion of brain. The patient is usually in 
a propped up position, dyspnoeic, tachypnoeic and diaphoretic and in air hunger 
due to lactic acidosis.  
  After the assessment of vital signs, the examination should be 
concentrated on the neck veins. Jugular venous pressure helps to assess the 
pressure within the right atrium. Most of the patients presenting with CHF have an 
elevated jugular venous pressure, which indicates the raised left ventricular filling 
pressure. The anterior chest wall should be carefully examined for the presence of 
dyskinetic area in the precardium, which may be indicative of the presence of   left 
ventricular aneurysm.  
  The position and character of the apical impulse should be 
determined, which may reveal the underlying cardiomegaly. Careful auscultation 
may reveal an early diastolic sound (S3), which suggests systolic dysfunction or a 
late diastolic sound (S4) may be heard in patients with preserved ejection fraction. 
A systolic murmur may be heard in the apex, suggesting a dilated left ventricle or 
mitral regurgitation. However, the severity of mitral insufficiency may not 
correlate with the intensity of the murmur. Examination should also focus on the 
lung fields to assess the degree of pulmonary congestion, manifesting as fine end 
inspiratory basal crackles. Percussion of the chest wall should be done and dullness 
in the base should be looked for to rule out pleural effusion.  
  Examination of the abdomen may reveal features suggestive of 
volume overload. The presence of ascites and tender hepatomegaly due to 
congestive liver caused by long standing right sided heart failure. Most of the 
patients present with peripheral oedema, however it should be taken as a sign of 
heart failure only in the presence of an elevated jugular venous pressure. The 
severity of congestion can be assessed by clinical, biochemical and dynamic 
manoeuvres. (Fig. 9)  
 
 
 
 
 
 
 
 
 
Fig. 9. Assessment of pulmonary and systemic congestion.Congestion grade: <1, 
none; 1-7, mild; 8-14, moderate; 15-20, severe. Edema: in the absence of other 
cause of edema. Orthopnea: 0, absent; 1, mild (use of one pillow); 2, moderate (use 
of more than one pillow); 3, severe: sleeps in an armchair on in a sitting position.  
Prognostic Indicators: 
 Blood pressure: 
   Results from the OPTIMIZE-HF study showed that there was a 
significant association between systolic blood pressure and mortality, across a wide 
variety of blood pressures. The mortality rate did not increase in patients with high 
blood pressure and the risk for mortality was lesser than that seen in patients with 
normal blood pressure.26 Patients with narrow pulse pressure are at higher risk for 
mortality and adverse outcomes than with wide pulse pressure. 
Renal function: 
  One of the most important prognostic indicators in patients with heart 
failure is renal function, assessed by glomerular filtration rate, urea and creatinine. 
Worsening renal function due to hypoperfusion of kidneys, in the presence of heart 
failure comes under a group of related disorders called cardio renal syndromes. 
The risk for both repeated hospitalizations and mortality increases with 
deteriorating renal function.27 
Biomarkers:  
  Brain natriuretic peptide (BNP) and N-terminal pro-BNP              
(NT-proBNP) are the established and strong predictors for risk of mortality in heart 
failure. In patients presenting with CHF, natriuretic peptide levels are powerful 
prognostic indicators of both long-term and short-term outcomes. BNP levels 
during admission predicted the in-hospital mortality and mortality at one year in 
patients with both reduced and preserved systolic function.  
Hyponatremia: 
  About one-fourth of patients presenting with CHF have mild 
hyponatremia, defined as serum sodium concentration of less than 135 mmol/litre, 
irrespective of their ejection fractions.28 Hyponatremia may be dilutional or 
hypervolemic. The risk for mortality and re-hospitalizations was found to be higher 
in patients with hyponatremia29 than normal levels. 
Body weight: 
  Increased body weight is a significant contributor to repeated 
hospitalizations in ambulatory patients, but not for mortality.30 Outcome of patients 
can be improved with appropriate mechanisms to remove the excess fluid.  
QRS duration:  
  Approximately 30 to 40 percentages of patients with acute heart 
failure and systolic dysfunction have an increased QRS duration of more than 120 
milliseconds. It is an indicator of left ventricular dysynchrony and is an 
independent predictor of mortality, in spite of appropriate treatment31 due to 
arrhythmias. 
Coronary Artery Disease: 
  Patients presenting with CHF due to CAD (Coronary Artery Disease) 
known as Ischemic dilated cardiomyopathies, have a poor prognosis than patients 
with heart failure due to other causes. Prognosis depends upon the extent and 
severity of vascular occlusion, presence of ischaemic or stunned myocardium, 
collateral formation, duration of ischemia and initial management of the 
patient.32,33 
Diagnostic Evaluation:  
  The pathophysiology of heart failure syndromes being complex, along 
with the frequent association of co morbidities, a number of specific investigations 
are required to make an accurate diagnosis. These include biochemical, 
radiological and interventional investigations.  
Biochemical and Haematological anlalysis:  
  Biochemical and haematological parameters are routinely measured in 
the initial assessment of patients with heart failure syndromes. These parameters 
provide essential information on the presence of co morbidities like anemia and 
infections that would precipitate and affect the evaluation and management of 
patients with CHF. Essential parameters like renal functions tests and electrolytes 
may have to be repeated throughout the course of hospital stay to look for cardio 
renal syndrome which is important in deciding the treatment modalities. The most 
common electrolyte disturbance is hyponatremia. About 20% of patients with heart 
failure have biochemical evidence of hyponatremia.34 However it has been found 
that correcting the sodium levels have not improved the clinical course of the 
patients35 but predicts mortality. In patients who have been treated for heart failure 
with diuretics, hypokalemia is common, which is associated with increased risk for 
cardiac arrhythmias. Hypomagnesemia and hypophosphatemia has also been 
documented.  
  Evaluation of renal function should be done for any patient admitted 
with heart failure and should be monitored periodically. Monitoring is important 
because renal hypoperfusion can occur with decreased cardiac output, which can 
decrease the glomerular filtration, leading to acute renal failure. Presence of risk 
factors like diabetes, hypertension and atherosclerosis further increase the 
possibility of developing renal failure. Apart from the cardiac failure per se, drugs 
like angiotensin converting enzyme inhibitors, angiotensin receptor antagonists and 
diuretics can cause elevation in the renal parameters. Dronedarone, used in the 
treatment of atrial fibrillation, can cause a rise in serum creatinine values and acute 
kidney injury.36 In patients with CHF, various studies have concluded that about 
60% to 70% have reduced glomerular filtration rate37 and 20% to 30% have raised 
serum creatinine.38 Deterioration of renal function during hospital stay is a potent 
indicator of adverse outcomes.  
  Diabetes mellitus is an important risk factor in heart failure due to 
both ischaemic and non-ischaemic aetiology. High levels of glucose in plasma 
indicate the presence of diabetes and also indicate failure of glycaemic control in 
already diagnosed patients. Derangements in liver function tests can occur due to 
haemodynamic alterations or drugs and should be monitored serially. Elevation of 
serum bilirubin is common in patients with acute decompensation and prolonged 
congestion leading to cardiac cirrhosis and portal hypertension.  
   Recent studies have shown that more than one-third of patients with 
heart failure are anaemic. Lower haemoglobin values have been related with 
decreased exercise capacity, severe symptoms and increased mortality. Anaemia 
can be a triggering factor for acute decompensation in a patient with chronic heart 
failure. Leucocyte count and differential count should be looked into in order to 
rule out infection as a precipitating factor for decompensation. 
  
 Electrocardiogram:  
  Electrocardiogram (ECG) is an essential component in the initial 
evaluation of patients with heart failure and also in patients who have been already 
diagnosed to have heart failure. The commonest finding during decompensation is 
the presence of sinus tachycardia due to the activation of the sympathetic nervous 
system. If the patient is already on beta blockers, the sympathetic response may be 
blunted. Arrhythmias can be a precipitating factor for decompensation, whose 
correction may dramatically improve the symptoms. In patients with systolic 
dysfunction, duration of QRS complex exceeding 120 milliseconds indicates 
ventricular dysynchrony and pro arrhythmic state. QRS duration of more than 120 
milliseconds is a major ECG criterion for indication of cardiac resynchronisation 
therapy. If left ventricular hypertrophy is present, it may indicate the cause of heart 
failure, including hypertension and valvular heart diseases. The presence of right 
ventricular hypertrophy indicates pulmonary hypertension, which may be primary 
or secondary. Previous myocardial infarction is evidenced by the presence of Q 
waves in the respective leads. 
 Chest Radiography:  
  In spite of the advent of newer techniques for the diagnosis of heart 
failure, chest radiography of the chest still remains to be one of the essential and 
gold standard investigations for diagnosing and monitoring treatment in heart 
failure and ruling out other causes. The classical appearance in chest radiography is 
the presence of perihilar butterfly pattern of alveolar opacities. The opacities fan 
out on both sides from the hilar pulmonary arteries to the lung peripheries. Though 
this is the hallmark finding of pulmonary congestion, most of the patients show 
only a subtle picture. These include increase in the interstitial marking, manifesting 
as Kerley B lines, which are horizontal linear opacities ranging up to the surface of 
the pleura. The other common findings are peribronchial cuffing and increase in 
the upper lobe vasculature and prominent pulmonary artery markings, which 
indicate pulmonary hypertension. Cardiomegaly can be made out with 
posteroanterior projection of the beam. The absence of an enlarged cardiac 
silhouette shows that the patient has preserved ejection fraction or the onset of 
systolic dysfunction is recent. Disproportionate or isolated enlargement of the left 
atrium increases the possibility of mitral valve disease. Enlargement of the right 
ventricle alone raises the possibility of pulmonary hypertension or right ventricular 
outflow tract obstruction. Calcification in the valves, coronaries or pericardium 
may indicate the cause of heart failure. Bilateral pleural effusion can also be made 
out. 
  
Echocardiography: 
  The single most useful investigation in the diagnosis and evaluation of 
patients with heart failure is 2D echocardiography. It is highly essential to establish 
the underlying cause of heart failure and to plan optimal management strategy for 
the patient. Two dimensional echocardiography easily diagnose cardiac structural 
abnormalities or decreased left ventricular systolic function and other cardiac 
anomalies responsible for heart failure. The left ventricular ejection fraction has 
been found to be one of the most potent indicators of poor prognosis. In patients 
with reduced ejection fraction, dilatation of the cardiac chambers is an important 
finding, as it alters the intracardiac haemodynamics and geometry.39 
Echocardiography also plays an important role in monitoring the response of 
patients to various modes of treatment.40-42 It is easily available and widely used 
diagnostic tool even at the bed side. 
  One of the most essential prognostic indicators is Left ventricular end 
diastolic volume which indicates increased left ventricular pressure. Its prognostic 
value holds good for both ischaemic and non-ischaemic cardiomyopathy. The 
success of biventricular pacing can be assessed by echocardiography. It can be 
achieved by assessing the reverse left ventricular remodeling and reduction in 
mitral regurgitation. Echocardiography can also predict patients who will be 
benefited by biventricular pacing. 
 Magnetic Resonance Imaging:  
  In the assessment of the anatomy and function of the heart, cardiac 
magnetic resonance imaging has emerged as an important complement to 
echocardiography. In the diagnosis of cardiomyopathies and myocarditis, magnetic 
resonance imaging is the imaging modality of choice, since it has the ability to 
detect myocardial infiltration, inflammation and scarring. In the setting of renal 
failure, when gadolinium contrast cannot be used, it can detect the areas of 
infarction and the viability of the myocardium. However, magnetic resonance 
imaging should not be performed in patients with pacemakers or implantable 
cardiac defibrillators.  
Treatment Of Heart Failure:  
  Management of heart failure is dealt with in three phases. Phase I 
occur in the ICU and deals with immediate stabilization and treatment. Phase II 
deals with continued management while in hospital and Phase III, the vulnerable 
phase deals with close monitoring in the early period post discharge, which is 
gaining more importance43 since this period is more important in predicting 
mortality, rehospitalization and adverse outcomes. Biomarkers are particularly 
useful in phase III which predicts the early adverse outcomes in the future. The 
approach to heart failure is depicted in the following figure. (Fig. 10) 
 
Fig. 10. Approach to a case of Heart failure 
  In phase I, goal is directed towards prompt recognition and 
management of life threatening condition like pulmonary oedema, cardiogenic 
shock and ventricular tachycardia, identification of the initiating mechanism and its 
prompt treatment and rapid symptom relief.44 Effort should be made to identify if it 
is the first episode or worsening of chronic heart failure. In the latter case, a patient 
is more likely to have a specific cause of HF, such as an acute myocardial 
infarction and one or more triggering factors. Based on blood pressure, patients can 
be divided as hypertensive when systolic BP>160 mm Hg, where presenting 
feature would be pulmonary oedema, hypotensive when systolic BP<90 mm Hg, 
when the patient may have right heart failure and normotensive, if patient has acute 
coronary syndrome. As dyspnea forms the most common symptomatology, the 
initial management starts with addressing respiratory issues.  
  After emergency treatment, in Phase II, patient is transferred to ward 
to relieve symptoms due to pulmonary and systemic congestion and for further 
workup and planning post discharge. Patients may continue to have breathlessness 
or volume overload signs like raised JVP, peripheral oedema or, pulmonary 
crackles, abnormal hemodynamics and neurohormonal mediators due to ventricular 
remodeling. Many patients get discharged with persistent symptoms with no 
reduction in body weight.45 Hence, treatment is to be continued until congestion 
gets relieved and patient reverts to a state of euvolemia and also function of the 
myocardium is to be assessed and patients stratified based on whether myocardium 
would recover function and treated accordingly. Blood pressure, daily weight and 
fluid balance are to be closely monitored. Serum electrolytes, Serum Uric acid, 
renal function tests, ABG (Arterial Blood Gas analysis) in case of hypoxia and 
troponin levels in ACS (Acute Coronary Syndromes) patients should be measured. 
Intravenous diuretics is converted to oral form and continued to relieve congestion. 
Treatment with diuretics is continued till congestive symptoms disappear and 
orthostatic changes and renal function trend necessitates discontinuation of the 
drug. 
  In patients refractory to pharmacologic therapy, excess water and 
sodium is removed by peripheral ultra filtration. Patients should be advised to 
undertake simple maneuvers like walking down a corridor or climbing a flight of 
stairs to assess exercise capacity before discharging the patient. Patient and family 
should be advised regarding life style modification.  
  Recurrent admissions are due mainly to early recurring of volume 
overload features or neurohormonal activation and effects of ventricular 
remodeling. Patients are to be followed up within one month following discharge. 
A closer follow up of within a week may be needed based on number of factors 
which influence readmission or death, the vulnerable phase at which prompt 
intervention may lead to reduced rehospitalization and reduced risk of death. Early 
follow up of at risk patients should include measuring blood pressure, renal 
function, body weight and BNP if possible and to modify therapy when needed. 
Drug non compliance may also lead to early recurrent pulmonary oedema in early 
post discharge period. 
 
BIOMARKERS IN HEART FAILURE  
  Over the past few decades, several cardiac biomarkers have been 
investigated and a few have been approved for the diagnosis of various cardiac 
conditions. Some of them also help in determining the future risk, short term and 
long term mortality. (Fig. 11) 
  A biomarker should fulfill the following criteria for its significant use 
in clinical practice. 
 The biomarker should be accurate with easy availability at a modest cost so 
that it can be repeated.  
 The biomarker should give information which cannot be retrieved by a 
thorough clinical examination.  
 The measured levels of the biomarker should be useful in making decisions 
regarding the management of the patient.  
  
Fig. 11. Biomarkers in Heart Failure  
  Though, only a few of the cardiac biomarkers satisfy the above 
mentioned criteria, most of these markers help in providing essential data involved 
in the pathogenesis of cardiac failure or they may be helpful in the diagnosis of 
cardiac failure. Some of these markers provide important information regarding the 
prognosis of the patients and may be useful in risk stratification. Many cardiac 
biomarkers may be involved in the pathogenesis, which may act as initiating or 
activating mechanisms, and hence, can be potential targets for specific therapy. 
The cardiac biomarkers can be classified into the following categories: 
inflammation, oxidative stress, extracellular matrix remodeling, neurohormones, 
myocyte injury, myocyte stress and novel markers (Fig 9).46 
Natriuretic Peptides In Heart Failure  
  Brain natriuretic peptide is a polypeptide with 32-aminoacids, which 
is secreted by the ventricles in response to stretching of the ventricular myocardial 
cells. Calcium ions helps and play a major role in the release of the natriuretic 
peptides.47 It was named so since it was first identified in the extracts of porcine 
brain. However, in humans, it is predominantly produced by the ventricular 
myocytes. Along with the brain natriuretic peptide, a biologically inactive 
fragment is also released, known as N-terminal fragment (NT-proBNP). The 
secreted brain natriuretic peptide binds to the atrial natriuretic factor receptors and 
activates them. The physiological actions of this peptide are to decrease the 
systemic vascular resistance and the central venous pressure by increasing 
natriuresis. The net effect of natriuretic peptide is a decrease in the net blood 
volume, leading to reduction in the systemic blood pressure and afterload 
(peripheral resistance), which causes an increase in contractility and the cardiac 
output by means of an increased ejection fraction.  
  It has been demonstrated in various studies that brain natriuretic 
peptide levels correlated very well with symptoms of heart failure47-51and remains 
an established cardiac biomarker. The level of natriuretic peptides correlates well 
with the left ventricular systolic function, assessed by the ejection fraction by 
means of echocardiography.  
  Certain large studies have shown that NT-proBNP is the most 
sensitive biomarker for the detection of mild left ventricular systolic dysfunction. 
However, since these patients were relatively asymptomatic, the clinical 
significance is unclear.52 Of all the biomarkers studied in heart failure, brain 
natriuretic peptide has emerged as the biomarker of choice in the diagnosis and risk 
stratification of patients with heart failure. 
 
 
Troponins In Heart Failure:  
  Over the past decade, troponins have emerged as the gold standard 
biomarker for the diagnosis of acute coronary syndromes (ACS), especially acute 
myocardial infarction. However, troponins may be elevated in conditions other 
than acute coronary syndromes. One such condition is heart failure. It has been 
proposed that cardiac troponins are strong predictors for poor prognosis and 
adverse outcomes throughout the spectrum of pathogenesis of heart failure 
syndromes.53 Troponin elevation has been on the rising trend  in patients with heart 
failure, even in the absence of significant coronary ischaemia. This situation 
complicates the interpretation of the elevated troponins in making the diagnosis of 
acute myocardial infarction. However troponins are still one of the important tools 
in the diagnosis of acute coronary syndromes. Recently, highly sensitive assays 
have been used to detect troponins, resulting in the increase of abnormal results in 
patients with heart failure.54-58 
  Troponins are special proteins essential for the control of both cardiac 
and skeletal muscle contraction. There are two chief proteins involved in the 
contraction-relaxation cycle of the muscles, namely actin and myosin. Calcium is 
essential for the initiation of contraction of muscles. It initiates muscle contraction 
through the troponin complex.  
 Fig.12. Troponin complex 
 
Fig. 13. Role of troponins in muscle contraction 
Measurement of Troponins  
  The troponin complex comprises three proteins namely Troponin C 
(calcium binding), Troponin T (tropomyosin binding proteins) and Troponin I 
(inhibitory) (Fig. 12).They are not involved in the contraction of smooth muscles. 
Separate genes are responsible for skeletal and cardiac isoforms and therefore, the 
isoforms vary in structure. Cardiac troponin I is not represented by damaged 
skeletal muscles and hence, it is highly specific for cardiac muscle injury.59,60  
 
  In the relaxed state, the binding site for actin with myosin is inhibited 
by the cardiac troponin I (cTnI). Binding of calcium with the cardiac troponin C 
(cTnC) initates a complex mechanism by which the cardiac troponin I uncovers the 
active binding site on the actin molecule, making it available for binding with the 
myosin chain resulting in contraction of the muscles. (Fig. 13)  
 
Background: Serum Uric Acid (UA) 
  Although the discussion regarding whether serum uric acid (UA) is a 
risk factor for the development of either cardiovascular disease or renal disease is 
currently controversial,61,62 its role as a prognostic risk marker for these diseases, 
especially for those with hypertension, diabetes mellitus or cardiac failure, seems 
to be well accepted. Higher UA levels are accepted as a progressive marker for the 
risk of developing either coronary heart diseases, or cerebrovascular accidents like 
stroke when comparing to the populations with normal uric acid concentration, 
particularly those in the lower one third of the physiological range. 61,63-73 
 
  An article published earlier by LK Niskanen's et al. showed that 
increased uric acid concentrations in serum were independent of the variables 
commonly associated with gout or metabolic syndrome in relation with 
cardiovascular disease mortality among middle aged men.73 Hyperuricemia in CHF 
is due to overproduction of uric acid in contrary to gout in which hyperuricemia is 
mainly due to decreaed renal excertion and hence the pathophysiology of 
hyperuricemia in CHF and gout varies. 
 
  There exist a controversy regarding whether serum uric acid is a risk 
factor or a risk marker, and also whether uric acid is an antioxidant or pro oxidant, 
but it is vital to understand that UA is associated with endothelial cell dysfunction 
or damage, reduced bioavailability of endothelial nitric oxide (eNO) and 
interaction with other toxic substrates and reactive oxygen species (ROS) of the A-
FLIGHT-U acronym, which can result in accelerated atherosclerosis (Fig. 14).74  
 
  Johnson RJ et al. shows that elevated serum uric acid concentrations 
can predict the development of future cardiovascular diseases among the general 
population, among the hypertensive individuals, and in those individuals with 
previous history of cardiovascular disease. Moreover it also showed that elevated 
serum uric acid can predict the occurrence of hypertension71 in general population. 
 Fig. 14. A-Flight-U Acronym 
  Some groups of patients are more prone to develop early 
cardiovascular disease due to premature atherosclerosis compared to the general 
population. They include Diabetes with accelerated atheroscleropathy, non-diabetic 
patients with accelerated atherosclerosis, decompensated cardiac failure patients 
with ischemic cardiomyopathy, metabolic syndrome patients (those with 
constellation of obesity, insulin resistance, impaired glucose tolerance, 
hypertension and dyslipidemia), chronic kidney disease patients, hypertensive 
patients, African American patients, those patients consuming long term diuretics, 
and those patients with excess alcohol consumption. Each of this patient groups 
have a specific mechanism which leads to their respective disease leading to 
hyperuricemia (Fig. 15)74 
 
Fig. 15. Hyperuricemia: clinical clusters at cardiovascular risk 
  Along with the common finding of increased oxidative-redox stress 
among these patient groups, they also exhibit insulin resistance and metabolic 
syndrome. 
URIC ACID METABOLISM 
  The final oxidation product after catabolism of purines in humans is 
uric acid. Urates are the ionized forms of uric acid and greater than 95% occur as 
mono sodium urate crystals at pH 7.4 in plasma extracellular fluid and synovial 
fluid.75 
  The pH of urine influences the solubility of uric acid in solutes to a 
major extent. Purines can be synthesized and catabolized in almost all tissues of 
the body, but urates can be produced only in those tissues with xanthine oxidase 
activity such as liver and small intestine. The amount of urate produced varies 
according to the amount of purines present in the diet and also according to the 
amount synthesized, metabolised or degraded. Normally around 75% of the urate 
produced is excreted by the kidneys and major portion of the remainder by the 
small intestine. 
  The kidneys utilize specific transporters like organic anion 
transporters (OATs) like urate transporter 1 (URATI) and human uric acid 
transporter (hUAT) to clear urate from the plasma and maintain physiologic 
balance. URAT1 and other OATs carry urate into the tubular cells through the 
apical side of the lumen, then after entering into the cell, passes to the basolateral 
side of the lumen by a process controlled by the voltage dependent carrier hUAT. 
 
  There are four steps in the handling of uric acid by the kidneys. The 
processes are 
(1) Glomerular filtration, 
(2) Tubular reabsorption 
(3) Secretion, and 
(4) Post-secretory reabsorption. 
  The anion transporter URAT1 is usually present at the apical brush 
border of the proximal nephron and are directly inhibited by uric acid compounds 
on the apical side of the tubular cell by the so-called cis-inhibition.76 The amount 
of total body urate is the net balance between urate production and urate excretion. 
The amount of urate produced varies directly according to the amount of purines 
ingested in the diet and also according to the amount synthesized, salvaged or 
degraded. Normally maximum amount of the urate produced is excreted by the 
kidneys and major portion of the remainder by the small intestine. Hyperuricemia 
can be caused by either increasing the production, decreasing the excretion, or by 
the combination of those mechanisms. When hyperuricemia exists, urate can 
precipitate in vivo and deposit in tissues as tophi. (Fig. 16) 
 Fig. 16. Uric acid turnover and metabolism 
HYPERURICEMIA 
  Based on the epidemiologically, physiochemical and disease burden 
criteria, hyperuricemia is defined as an elevation of plasma (or serum ) urate level 
greater than 420 umol/L (7.0 mg/dL). Epidemiologically considering, 
hyperuricemia can be defined as a mean plus two standard elevations of serum uric 
acid values from a randomly selected population. When estimated among the 
unselected population, 95% of them have a serum uric acid less than 420 umol/L 
(7.0 mg/dL). Considering physicochemically, hyperuricemia is the amount of urate 
in the plasma which exceed the solubility limits of monosodium urate >415 umol/L 
(6.8 mg/dL). 
  Lastly, we can define hyperuricemia according to the risk of 
developing disease. The chance of an individual developing urolithiasis or gouty 
arthritis increases 3 fold when the urate concentration in the blood exceeds         
420 umol/L (7.0 mg/dL) and increases in direct proportion to further increase in 
the concentrations > 7.0 mg/dl. Hyperuricemia is present in around 2.0 to 13.2% of 
ambulatory adults and to an increased frequency in hospitalized individuals. 77 
Causes of Hyperuricemia 
  Hyperuricemia can be caused by either a primary (when the cause is 
due to an innate mechanism) or a secondary (due to any acquired disorder) 
mechanism. But it is more useful to classify hyperuricemia based on the 
circumstances that lead to the elevation in serum uric acid such as either increased 
urate production, or reduced urate excretion or a combination of the above two 
mechanisms. 
Pathophysiological Classification of Hyperuricemia: 
1) Urate overproduction 
 a) Primary idiopathic 
 b) HPRT deficiency 
 c) PRPP synthetase overactivity 
 d) Hemolytic process 
 e) Lymphoproliferative diseases 
 f) Myeloproliferative diseases 
 g) Psoriasis 
 h) Paget’s disease 
 i) Glycogenosis III, V, and VII 
 j) Rhabdomyolysis 
 k) Exercise 
 l) Alcohol 
 m) Obesity 
 n) Purine-rich diet 
2) Decreased Uric acid Excretion 
 a) Primary idiopathic 
 b) Renal insufficiency 
 c) Polycystic kidney disease 
 d) Hypertension 
 e) Acidosis 
  i) Lactic acidosis 
  ii) Diabetic ketoacidosis 
 f) Starvation ketosis 
 g) Berylliosis 
 h) Sarcoidosis 
 i) Lead intoxication 
 j) Hyperparathyroidism 
 k) Hypothyroidism 
 l) Toxaemia of pregnancy 
 m) Bartter’s syndrome 
 n) Down syndrome 
 o) Drug ingestion 
  i) Salicylates (>2g/d) 
  ii) Diuretics 
  iii) Alcohol 
  iv) Levodopa 
  v) Ethambutol 
  vi) Pyrazinamide 
  vii) Nicotinic acid 
  viii) Cyclosporine 
3) Combined Mechanism 
 a) Glucose-6- phosphatase deficiency 
 b) Fructose-1- phosphate aldolase deficiency 
 c) Alcohol 
 d) Shock   
Increased Urate Production 
  The purine content in the diet is an exogenous source of purines and 
contributes to the major source of urate in the body. Dietary restriction of purines 
itself approximately decreases serum urate level by 60umol/L (1.0 mg/dL) and 
decreases the excretion of uric acid in the urine by atleast 200 mg/day. The food 
items with high nucleic acid content contributes significantly to more serum urate 
concentration, because about 50% of ingested RNA purine and 25% of ingested 
DNA purine is metabolized into the urine as uric acid. Examples of such foods rich 
in purines include liver, "sweetbreads" (i.e., thymus and pancreas), kidney, and 
anchovy. 
  The serum urate level is also enhanced by endogenous sources of 
purine production which contributes less than dietary purines. De novo purine 
biosynthesis is an eleven-step process that results in formation of inosine 
monophosphate (IMP) and the formation of purine ring from non purine ring 
structures. The initial step is the combination of phosphoribosylpyrophosphate 
(PRPP) with glutamine and is catalyzed by amidophosphoribosyltransferase 
(amidoPRT) which is the rate limiting step and plays a major role in purine 
biosynthesis and urate production. (Fig. 17) 
 Fig. 17. De novo biosynthesis and metabolism of Purine nucleotides 
1- Phosphoribosylpyrophosphate(PRPP) synthetase 
2- Amidophosphoribosyltransferase (amidoPRT) 
3- Adenylosuccinate lyase 
4- (myo-)adenylate (AMP) deaminase 
5- 5’-nucleotidase 
6- Adenosine deaminase 
7- Purine nucleoside phosphorylase 
8- Hypoxanthine phosphoribosyltransferase (HPRT) 
9- Adenine phosphoribosyltransferase (APRT) 
10- Xanthine oxidase    
  Another regulatory pathway in purine synthesis involves the salvage 
of purine bases by enzyme hypoxanthine phosphoribosyltransferase (HPRT). 
HPRT catalyzes the reaction of the purine bases hypoxanthine and guanine with 
PRPP to form the ribonucleotides Inosine monophosphate (IMP) and guanosine 
monophosphate (GMP) respectively. Increased salvage activity of HPRT increases 
the IMP and GMP concentrations and decreases the de novo synthesis of purines 
and uric acid, thus retards de novo synthesis by increasing the concentrations of 
inhibitory ribonucleotides.77 
  Serum urate levels are proportional to the rates of de novo purine 
biosynthesis, which is determined by the level of PRPP, as evidenced by the 
occurrence of two inborn errors of purine metabolism. Increased PRPP synthetase 
activity and HPRT deficiency are associated with increased production of purines, 
hyperuricemia, and hyperuricaciduria. An inborn error of purine synthesis can lead 
to increase uric acid production. An X-linked disorder that causes an increase in 
the activity of the enzyme PRPP synthetase can lead to increased PRPP production 
and accelerated de novo biosynthesis. PRPP is the substrate and allosteric activator 
of amidoPRT, which is the first and rate limiting enzyme in the de novo pathway. 
  Another inborn error of de novo purine synthesis leading to 
hyperuricemia is HPRT deficiency, which is also an X-linked disorder which 
enhances urate biosynthesis in two ways. Firstly PRPP is accumulated as a result 
of a decrease in utilization in the salvage pathway which in turn, provides 
increased substrate for amidoPRT and de novo biosynthesis. Secondly in addition, 
reduced formation of the nucleoside monophosphates, IMP and GMP, through the 
salvage pathway impairs feedback inhibition on amidoPRT, further enhancing de 
novo biosynthesis leading to hyperuricemia. 
  Accelerated purine nucleotide degradation may also cause acute 
hyperuricemia, as a part of tumour lysis syndrome which is a medical emergency 
i.e., with conditions of rapid cell turnover, proliferation, or cell death, as in 
leukemic blast crisis, cytotoxic therapy in malignancy, hemolysis, or 
rhabdomyolysis. The nucleic acids released from cells are metabolized rapidly by 
nucleases and phosphodiesterases, forming increased uric acid levels. 
  Hyperuricemia can also occur via catabolic pathways by the 
breakdown of ATP of skeletal muscle after strenuous exercise or seizure activity. It 
is also seen in glycogen storage diseases type III, V and VII. Serum uric acid is 
also increased in acute stressful situations like myocardial infarction, 
cerebrovascular accident, acute respiratory failure and in smoke inhalation, all of 
which leads to increased catabolism of ATP.77 
Decreased Uric Acid Excretion 
  Majority of individuals with hyperuricemia have a defect in the renal 
excretion of uric acid. In gout, the hyperuricemia is mainly due to decreased urate 
clearance to glomerular filtration rate (or urate to insulin clearance rate). Thus, 
gouty individuals excrete about 40% less uric acid than nongouty individuals for 
any given plasma urate concentration. Uric acid excretion increases in both gouty 
and nongouty individuals when plasma urate levels are increased beyond 7 mg/dl, 
but in those with gout, plasma urate concentrations should be 1 to 2 mg/dL higher 
than normal to achieve near equivalent uric acid excretion rates.77 
  Abnormal uric acid excretion can result due to either of three 
mechanisms: reduced glomerular filtration, increased reabsorption or decreased 
tubular secretion. Reduced urate filtration does not cause primary hyperuricemia 
but it contributes to the elevation in uric acid in renal dysfunction. Hyperuricemia 
is invariably present in chronic kidney disease, but the correlation between uric 
acid levels and glomerular filtration rate is poor. Uric acid excretion per unit of 
glomerular filtration rate gradually increases progressively, tubular reabsorptive 
capacity is reduced, and the extrarenal clearance of uric acid increases but tubular 
secretory capacity tends to be preserved as kidney damage becomes more severe in 
chronic kidney disease. The secondary hyperuricemia found in acidosis is due to 
the decreased tubular secretion of uric acid. 
  Alcohol intoxication, starvation, diabetic ketoacidosis, salicylate 
poisoning and lactic acidosis all lead to accumulation of acids such as acetate, 
acetoacetate, β hydoxybutyrate, salicylates and lactate indirectly leading to 
hyperuricemia by competing with uric acid for tubular secretion. Hyperuricemia 
can also be due to increased reabsorption of urate at a site distal to its tubular 
secretion which is responsible for the hyperuricemia of extracellular volume 
depletion which occurs with diabetes insipidus or diuretic therapy.77 
Combined Mechanisms 
  Both increased urate production and decreased uric acid excretion can 
together contribute to hyperuricemia. In individuals with a deficiency of glucose-6- 
phosphatase (an enzyme that hydrolyzes glucose-6- phosphate to glucose), increase 
in urate production results from accelerated ATP degradation at times of fasting or 
hypoglycaemia and in addition, the lower levels of nucleoside monophosphates 
decrease feedback inhibition by amidoPRT, further increasing de novo 
biosynthesis. These patients are hyperuricemic from infancy itself and develop 
early gout. These individuals also develop hyperlacticacidemia, which block uric 
acid excretion by reducing tubular secretion. 
  Patients with hereditary fructose intolerance caused by fructose-1-
phosphate aldolase deficiency produce hyperuricemia by both mechanisms. In 
these patients, the heterozygous state occurs in 0.5 to 1.5%, which is relatively a 
common cause of familial gout.77  In  homozygous states, fructose ingestion causes 
vomiting and hypoglycemia leading to hepatic failure and proximal renal tubular 
dysfunction. Ingestion of fructose, the substrate for the enzyme causes 
accumulation of fructose-1-phosphate because of enzyme deficiency causes ATP 
depletion, accelerated purine nucleotide catabolism, and leading to hyperuricemia. 
Both lactic acidosis and renal tubular acidosis contribute to urate retention. Those 
heterozygous carriers develop hyperuricemia, and only one-third develop gout.  
  Alcohol can also promote hyperuricemia by both mechanisms. Excess 
alcohol consumption causes hepatic breakdown of ATP and can increase urate 
production. Alcohol consumption may also induce hyperlacticacidemia, which can 
block uric acid secretion indirectly resulting in high uric acid levels. The higher 
purine content in some alcoholic beverages such as beer can also cause 
hyperuricemia. 
Uric acid, Metabolic syndrome, Diabetes mellitus, and 
Atheroscleropathy 
  Kylin et al. in 1923 first highlighted the significance of clustering the 
group of metabolic disorders namely: hyperglycemia, hypertension and 
hyperuricemia.76 After the information from seminal Banting lecture, Reaven GM 
in 1988, noted the major role of insulin resistance and described Syndrome X, 
which is now also known as insulin resistance syndrome (IRS) or metabolic 
syndrome(MS).78 Reaven GM and Zavaroni I et al in 1993, seventy years after 
Kylin described the clustering phenomenon, suggested that hyperuricemia is also  
included along with the metabolic and hemodynamic abnormalities associated with 
hyperinsuinemia of syndrome X or IRS.79 
  Hyperglycemia, hyperinsulinemia, hypertension and dyslipidemia are 
the major components of metabolic syndrome. It is well established that each one 
of these factors individually can be risk factor for cardiovascular mortality and 
morbidity, but together they forms a deadly quartet that causes premature 
atheroscleropathy in non-diabetics as well as the atherosclerosis related to 
metabolic syndrome. 
  It can also be noted that uric acid is linked to chronic inflammation. 
Hyperuricemia, highly sensitive C reactive protein (hsCRP), reactive oxygen 
species (ROS) and homocysteine act concordantly to accelerate the atherosclerosis 
associated with syndrome X. They cause remodeling of the arterial vessel wall 
endothelial lining causing atherosclerosis progression. The syndrome X has been 
known by multiple names and has been renamed numerous times, highlighting its 
significance in determining cardiovascular morbidity and mortality. In order to 
help the clinicians to workup for increased risk for cardiovascular mortality, these 
factors had been included in the National Cholesterol Educational Program- Adult 
Treatment Panel III (NCEP ATP III) guidelines recently.76,78-80 
Hyperinsulinemia and Hyperamylinemia 
  The renin angiotensin aldosterone system is activated by insulin, 
proinsulin and amylin, synergistically, to produce angiotensin II. Angiotensin II is 
one the most powerful inducers of the enzyme NAD(P)H oxidase resulting in 
increase of NAD(P)H levels, leading on to an increase in vascular reactive oxygen 
species and free radicals like superoxide (O2-).80,81 Thus Hyperinsulinemia in 
addition to retention of water, sodium, potassium, also causes hyperuricemia which 
causes many deleterious effects of free radical injury. (Fig. 18)82 
 
 Fig. 18. Deleterious effects of Hyperinsulinemia 
Hypertension 
  Studies have shown that hyperuricemia is strongly associated with 
hypertension. It has found that about 25% of untreated hypertensives, 50% of those 
treated with diuretics and 75% of those who presented with malignant hypertension 
have evidence of hyperuricemia.83 The proposed explanations for the relation 
between hyperuricemia and hypertension are: 
1. Urate reabsorption is stimulated by decreased GFR in hypertensives. 
2. Ischemia of the tissue caused by hypertensive microvascular disease. 
3. Increased lactate production due to the ischemia, competes with urate for tubular 
secretion. 
4. Increased breakdown of RNA-DNA leading to increased catabolism of purines 
causing increased uric acid by the exaggerated action of xanthine oxidase in 
hypertensive individuals. (malignant hypertension) 
5. Xanthine oxidase and ROS is induced by the presence of ischemia which leads 
to increased uric acid levels. This explains the possible cause for the rise in uric 
acid levels in congestive cardiac failure and preeclampsia. 
  Lin KC et al studied that blood pressure levels and serum uric acid 
levels were synergistically indicative of cardiovascular morbidity.84 Experiments 
done in two separate laboratories on rats showed that the rats developed systemic 
hypertension along with hyperuricemia when administered uricase inhibitor 
(oxonic acid).85,86 It proved that this elevated blood pressure was associated with an 
elevated renin levels and decreased levels of neuronal nitric oxide synthase in the 
juxta glomerular apparatus which has vasodilatory effect. Prevention of this 
hypertension may be attained by the addition of ACE inhibitors and L-arginine to a 
minor extent. It had been proved experimentally that the addition of allopurinol or 
uricosuric agents such as benziodrone to control the uric acid levels were able to 
control the elevated blood pressure in experimental models demonstrating the role 
of uric acid in the development of hypertension and vascular disease.71 
Obesity 
  It is known from the studies that leptin levels are increased in insulin 
resistance associated with metabolic syndrome and type 2 diabetes mellitus (DM).  
Bedir A et al outlined that leptins are involved in the regulation of serum uric acid 
levels in humans. They postulated that leptins could provide the link between 
hyperuricemia and obesity.87 It is also to be noted that increased free fatty acids 
and elevated triglycerides were also associated with hyperuricemia independently 
of body fat distribution and obesity.88,89 
Hyperglycemia 
  Uric acid acts as an anti-oxidant at normal serum glucose levels but 
converts into a pro coagulant during elevated sugar levels known as paradoxical 
anti-oxidant – pro oxidant switch by urate redox shuttle. This is because 
hyperglycemia induces both an oxidative and reductive stress on the arterial wall. 
Oxidative stress by the advanced glycosylation end products and reactive oxygen 
species ends in glucose auto oxidation leading to pseudohypoxia resulting in the  
accumulation of NADH and NAD(P)H within the vascular intima.80,90,91 The 
naturally occurring local anti-oxidants such as catalyse, SOD or GPX are utilized 
excessively in these reactions and once these are burnt out, uric acid is free to 
undergo the paradoxical antioxidant-prooxidant switch in the urate redox 
shuttle.92,93 
Homocysteine 
  In patients with premature atherosclerosis there exist a direct 
correlation between serum uric acid concentrations and homocysteine 
concentrations. Both act synergistically, particularly in those thrombotic 
atherosclerotic plaques which are more prone for rupture due to the depletion of 
local antioxidants due to increased redox stress.94-96 
Uric acid and Heart failure 
  Studies have shown that ischemia in heart failure triggers xanthine 
oxidase activity which ultimately ends in two products. Firstly, xanthine oxidase is 
involved in the conversion of hypoxanthine and xanthine to uric acid formation. 
Secondly, xanthine oxidase ends in the formation of reactive oxygen species and 
free radicals. Thus serum uric acid levels reflect the circulating xanthine oxidase 
activity and oxidative stress production in heart failure. There are studies which 
demonstrate the development of heart failure after myocardial infarction which are 
associated with hyperuricemia.97 But, yet, the role of uric acid in coronary artery 
disease and heart failure has not yet been clear and to be proven strongly. Some 
studies reported an independent association between uric acid and coronary artery 
disease, but others found its association only in females.98 Hence further studies are 
needed to confirm the association between uric acid levels with heart failure. 
  Uric acid functions as an antioxidant and probably one of the most 
important antioxidants in the plasma. Urate scavenges superoxide, hydroxyl 
radical, and singlet oxygen and chelates transition metals. Peroxynitrite is a 
particularly toxic product formed by the reaction of superoxide anion with nitric 
oxide which injures cells by nitrosylating tyrosine residues of proteins and 
mitochondrial injury. Uric acid may also block this reaction and functions as an 
anti oxidant. 
  Uric acid also prevents the degradation of superoxide dismutase, an 
enzyme critical in maintaining endothelial and vascular functions. Superoxide 
dismutase 3 is an extracellular enzyme which catalyses the reaction of superoxide 
anion to hydrogen peroxide thus protecting the cells from free radical injury.99 The 
removal of superoxide anion by superoxide dismutase 3 prevents the inactivation 
of the endothelial vasodilator, nitric oxide. Uric acid thus helps to maintain nitric 
oxide levels and endothelial function through superoxide dismutase. Normally, 
superoxide dismutase 3 (SOD 3) is inactivated in the presence of hydrogen 
peroxide by feedback inhibition. Uric acid blocks this feedback inactivation by 
hydrogen peroxide by regenerating SOD3 with the production of a urate radical. 
This latter radical, although potentially a pro-oxidant, has been found to be less 
reactive than the classic antioxidants and can be rapidly regenerated back to urate 
in the presence of ascorbate. The increase in serum uric acid levels in subjects with 
cardiovascular disease therefore explain that hyperuricemia in heart failure is a 
compensatory mechanism to counter oxidative stress. 
  Uric acid may also be responsible for endothelial dysfunction. Studies 
have reported that uric acid infusion in healthy humans resulted in decremental 
acetylcholine induced vasodilatation in the forearm thereby highlighting impaired 
endothelial nitric oxide release. Whereas uric acid is considered as an antioxidant, 
it also acts as a prooxidant under certain conditions, especially when other 
antioxidants are low thus explaining the anti coagulant- pro coagulant switch.99,100 
  Studies have shown that free radicals and oxidative stress are involved 
in the pathophysiology of heart failure. Exponential increase in myocardial 
oxidative stress in heart failure leads to the development of subcellular 
abnormalities leading to cardiomyopathic changes, depressed contractile 
function.101 The enzyme xanthine oxidase triggered during ischmia in heart failure 
catalyses the two terminal steps of uric acid synthesis, from hypoxanthine to 
xanthine and from xanthine to uric acid. These two steps also generate reactive 
oxygen species and thus uric acid is recognized indirectly as a marker of excess 
free radicals and reactive oxygen species, playing a key role in the pathogenesis of 
heart failure.2 
  Serum uric acid appears to increases in patients with congestive heart 
failure and serves as a valid prognostic biomarker in various studies. Increased 
serum uric acid levels are responsible for increased vascular tone and impaired 
contractility in heart failure through increased xanthine oxidase activity induced 
free radical stress. Thus uric acid is responsible for metabolic, functional and 
hemodymanic derangements in heart failure.102  Experiments are under trial that 
the drug Oxipurinol, the active metabolite of allopurinol, a potent xanthine oxidase 
inhibitor, is under research as a newer agent for the treatment of heart failure.2 
  Numerous modern cardiac biomarkers capable of predicting prognosis 
in heart failure are assessed only by research tests that are not widely available and 
are expensive. But uric acid being simple, widely available and of low cost serve 
as a valid prognostic marker for heart failure can be measured anywhere. In heart 
failure, uric acid levels are reflective of oxidative stress, impaired vasomotor tone, 
endothelial dysfunction, inflammatory cytokines activation and 
hyperinsulinemia.101The relationship of uric acid with renal function and diuretics 
increases the value of uric acid as a prognostic marker in heart failure.103 
  The most recognized complication of hyperuricemia is acute and 
chronic gouty arthritis. Hyperuricemia also causes kidney diseases like 
nephrolithiasis, urate nephropathy due to deposition of monosodium urate crystals 
in the renal interstitium and uric acid nephropathy, a reversible cause of acute 
kidney injury due to deposition of uric acid crystals in collecting ducts, renal pelvis 
and ureters.  
  Studies have shown that uric acid is a biomarker of negative prognosis 
in heart failure of varying severity.101,104 Uric acid levels are elevated in heart 
failure and gives accurate prognostic evidence.3 An ischemic heart induces 
oxidative stress and xanthine oxidase release due to reduced perfusion, as reflected 
by hyperuricemia which runs in vicious cycle that is responsible for heart failure 
pathogenesis.101,105 Adenosine synthesized in response to hypoxia by ventricular 
myocardial cells is being broken down to uric acid which enters vascular lumen 
due to low intracellular pH and negative membrane potential.106 Xanthine oxidase 
and uric acid levels are increased in vivo during ischemic conditions and hence 
elevated uric acid levels are implicated as a marker of tissue ischemia.107,108 In 
heart failure, hypoxia caused by transient coronary occlusion causes 
hyperuricemia.104 
  A Study of tourniquet induced lower limb exsanguinations in patients 
undergoing surgery shows fivefold exaggerated xanthine oxidase activity and uric 
acid for atleast two hours.109 Studies demonstrated urate crystals deposition in the 
proliferated intima of arterioles and in thrombi which represents the role of uric 
acid in the pathogenesis of vascular degeneration.110 Emerging evidences suggest 
that there is an imbalance between oxidative stress and NO generation in heart 
failure (nitroso redox imbalance). Xanthine oxidase in the cardiac ventricular 
myocytes causes pathological hypertrophy and increased apoptosis which impairs 
matrix structure. Hence it is proved that not only free radicals but also reduced 
endothelial NO causes the progression of heart failure. In this situation, xanthine 
oxidase interacts with NO signaling at various levels including neuronal NO 
synthase (NOS1) in the sarcoplasmic reticulum. Deficiency or translocation of 
NOS1 leads to increased xanthine oxidase which in turn impairs excitation 
contraction coupling and myofilament calcium sensitivity.111 Free radical induced 
breakdown of NO can blunt the Frank – starling response in the heart and it may be 
a mechanism of decreased heart function through hyperuricemia.112 The following 
picture depicts the mechanism of hyperuricemia in heart failure. (Fig. 19) 
 
Fig. 19. Mechanism of hyperuricemia in heart failure. 
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  According to the acute coronary syndrome study,113 there is a close 
correlation between serum uric acid levels and functional (NYHA) classification in 
patients with heart failure. Patients with adverse outcomes had hyperuricemia at 
the initial presentation. Bickel C et al had proven that for every 1 mg/dl increase in 
uric acid, there is 26% increase in mortality.114 Sinisa car et al.115 showed that 
hyperuricemia was associated with higher in-hospital and 30 days mortality, 
frequent hospitalizations and reduced life span in heart failure patients. 
 
  The LIFE (Losartan Intervention For Endpoint reduction in 
Hypertension) study had proven that reducing uric acid levels by losartan was 
associated with beneficial effect on cardiovascular outcome.116 The uric acid 
lowering effect of atorvastatin may also have contributed to the decrease in cardio 
vascular adverse outcomes and mortality in GREASE study (Greek Atorvastatin 
and Coronary Heart Disease Evaluation Study).117 Therefore any drugs that lower 
serum uric acid levels may be beneficial in the treatment of heart failure to reduce 
oxidative stress and long term mortality. However there are no reports whether uric 
acid is produced in the failing human heart and whether uric acid levels should be 
routinely measured in patients with heart failure or long term benefits. 
 
  This study has been done to find out whether the serum uric acid 
levels are elevated in heart failure, to correlate the uric acid levels with ejection 
fraction, to find its relation with functional class (NYHA classification), to study 
the association of serum uric acid levels with risk factors for heart failure and to 
note the prognostic importance of uric acid by relating it with 30 day mortality in 
heart failure patients.  
 
  
  
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
  
MATERIALS & METHODOLOGY 
Study Design: Observational Study  
Patient selection: 100 patients admitted at Coimbatore Medical College Hospital 
with Heart Failure during the time period from 1st August 2013 to 31st July 2014. 
Inclusion criteria:  
 Patients admitted with symptoms and signs of Heart Failure 
 Age group of both sexes > 18 years 
Exclusion criteria:  
 Acute Coronary Syndromes  
 Recent myocardial infarction or angina (< 1 month)  
 Chronic obstructive pulmonary disease 
 Chronic renal failure (Sr. creatinine> 2mg/dl)  
 Haematologal malignancies 
 Already diagnosed hyperuricemic patients 
 Patients on uricosuric drugs 
Techniques:  
Consent: 
  The study groups identified by the above criteria (inclusion and 
exclusion) were first informed about the nature of the study. Participants willing 
for the study were selected after getting an informed and written consent from 
them. Thus, a total of 100 patients were taken up for study who satisfied the 
inclusion and exclusion criteria. There was no conflict of interest and financial 
support was Nil. 
History and Examination: 
  Detailed history regarding risk factors, symptoms, signs and 
aggravating factors of heart failure were recorded and the patients are graded as per 
NYHA functional classification. Past history of myocardial infarction was also 
noted. Vital signs were recorded and clinical examinations of all the systems were 
made.  
Serum Uric acid Measurements: 
  Serum samples for Uric acid measurements were collected within six 
hours of admission. Serum uric acid levels will be measured with an autoanalyser 
that uses a phosphotungstic reagent.  
Reference Values for Serum Uric acid levels:  
In Men: 3.5 - 7.0 mg/dL 
In Women: 2.5 - 6.0 mg/dL 
  Hyperuricemia is defined as serum uric acid levels >7 mg/dL in males 
and >6 mg/dL in females. 
 
 
Electrocardiogram: 
  Electrocardiogram was performed for all patients to rule out acute 
coronary syndromes and to identify previous Myocardial Infarction. The QRS 
duration in all the patients was measured and compared with serum uric acid 
levels. 
Echocardiogram:  
  Echocardiogram was performed in all patients included in the study to 
assess the degree of cardiac dysfunction (LV ejection fraction) and to identify 
previous myocardial infarction. 
Patient Short Term Outcome:  
  All patients included in the study were followed up for a period of one 
month to assess the mortality rate after one month and re hospitalization within one 
month. 
Statistical Analysis: 
  Data was entered in Microsoft excel spread sheet and analyzed 
statistically using SPSS 20.0 software package. Significance testing of the 
difference between means was done by unpaired 2 tailed student ‘t’- test for 
independent samples, and correlations were estimated by Pearson coefficient. 
Significance was considered, if the ‘p’ value was below 0.05. 
 
  
 
 
 
 
 
 
 
 
RESULTS 
  
RESULTS: 
TABLE 1. AGE WISE DISTRIBUTION 
 
Age category 
(years) 
No. of patients 
(n=100) 
21-30 6 
31-40 19 
41-50 23 
51-60 27 
61-70 16 
>70 9 
 
 
 In this study of 100 patients, majority of the patients were in fourth 
and sixth decades. 
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Chart 1. Age wise distribution
TABLE 2. SEX DISTRIBUTION 
Sex 
No. of patients 
(n=100) 
Male 62 
Female 38 
 
 
 In the study group, majority of the patients were males comprising 
about 62% and females about 38%. 
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TABLE 3. URIC ACID LEVELS IN HEART FAILURE 
 
Normouricemia Hyperuricemia 
27% 73% 
  
 
 
 This study proves that serum uric acid levels were elevated in heart 
failure with results showing that majority 73% had hyperuricemia and minority 
27% had normal uric acid levels. 
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TABLE 4. URIC ACID AND SEX DISTRIBUTION 
 
 
 
 In this study, out of 32 females, 34 had hyperuricemia and only 4 had 
normouricemia. And out of 68 males, 39 had hyperuricemia and 29 had normal 
uric acid levels showing that prevalence of hyperuricemia was greater in females 
compared to males. 
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Chart 4. Uric acid and sex distribution
Female
Male
 
Sex 
Uric Acid (mg/dl) 
TOTAL 
≤6 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Female 4 2 7 18 7 38 
Male 15 8 16 13 10 62 
Total 19 10 23 31 17 100 
TABLE 5. EJECTION FRACTION IN HEART FAILURE 
LVEF % No. of patients 
≥50 9 
40-49 41 
30-39 39 
<30 11 
 
 
 
 Majority of the patients with heart failure in this study had ejection 
fraction in the range of 30 % – 49 % with 41 people in the EF range of 40 – 49 % 
and 39 people in the EF range of 30 – 39 %. 
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Chart 5. Ejection fraction in Heart Failure
TABLE 6. URIC ACID AND LVEF 
 
 
LVEF 
% 
Uric Acid (mg/dl) 
p value 
Pearson 
Correlation 
Coefficient 
≤6 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
≥50 9 0 0 0 0 
< 0.01 
 
 
 
- 0.853 
40-49 10 9 15 7 0 
30-39 0 1 8 21 9 
<30 0 0 0 3 8 
 
 
 
 
 The serum UA levels were compared with various grades of LVEF. In 
patients with decreased ejection fraction, all the patients (100%) had significant 
rise in serum UA. As the ejection fraction increased, the number of patients with 
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elevated serum uric acid levels proportionately decreased (0% in patients with 
EF>50). This association holds good with a P value of <0.01 and Pearson 
correlation coefficient of – 0.853. Thus this study shows that elevated uric acid 
levels had negative correlation with ejection fraction proving that progressive 
hyperuricemia indicates cardiac dysfunction in heart failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 7. MEAN URIC ACID LEVELS AND LVEF 
LVEF % 
Mean Uric acid 
levels (mg/dl) 
≥50 5.7 
40-49 6.9 
30-39 8.4 
<30 9.1 
 
 
 
 The mean UA levels of patients with different ejection fractions were 
compared. There was significant rise of serum UA levels in patients with reduced 
ejection fraction. The mean UA levels of patients with LVEF of >50%, 40-49%, 
50-59% and <30% are 5.7, 6.9, 8.4 and 9.1 mg/dL respectively. These results also 
show that serum uric acid levels correlate negatively with ejection fraction in heart 
failure. 
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Chart 7. Mean Uric acid levels
TABLE 8. URIC ACID AND NYHA CLASS 
Uric acid 
NYHA Class 
p value 
I II III IV 
≤6 5 10 3 1 
< 0.01 
6.1-7.0 1 3 6 0 
7.1-8.0 0 1 21 1 
8.1-9.0 0 0 17 14 
>9.0 0 0 4 13 
Total 6 14 51 29 
 
 
 The serum UA levels were compared with various grades of NYHA 
functional class in HF. In patients with grade III and IV NYHA, majority had 
significant rise in serum UA. As the NYHA fuctional class increases, the number 
of patients with elevated serum uric acid levels proportionately increases. This 
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Chart 8. Uric acid and NYHA class
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association holds good with a P value of <0.01. Thus this study shows that elevated 
uric acid levels had positive correlation with NYHA functional class proving that 
hyperuricemia indicates progression of the disease in heart failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 9. NYHA CLASS AND MEAN URIC ACID LEVELS 
NYHA Class Mean Uric acid 
levels (mg/dl) 
I 5.8 
II 6.5 
III 7.2 
IV 8.8 
 
 
 
 The mean UA levels of patients with different NYHA functional class 
were compared. There was a progressive rise of serum UA levels from grade I to 
grade IV NYHA functional class in HF patients. The mean UA levels of patients 
with NYHA grade I, II, III and IV are 5.8, 6.5, 7.2 and 8.8 mg/dL respectively. 
These results prove that serum uric acid levels correlate positively with NYHA 
functional class in heart failure. 
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TABLE 10. ETIOLOGY OF HEART FAILURE 
 
Etiology No. of patients 
Ischaemic Heart Disease 61 
Rheumatic Heart Disease 23 
Heart Failure with Preserved EF 8 
Congenital Heart Disease 8 
 
 
  In the study, majority (61%) had ischemic cardiomyopathy as the 
cause of HF, with Rheumatic heart disease comprising about 23 %. 
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TABLE 11. URIC ACID IN ACUTE AND CHRONIC HEART FAILURE 
 
Uric acid (mg/dl) Acute Heart Failure Chronic Heart Failure p value 
≤6 1 18 
< 0.01 
6.1-7.0 0 10 
7.1-8.0 2 21 
8.1-9.0 17 14 
>9.0 15 2 
Total 35 65 
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TABLE 12. MEAN URIC ACID LEVELS IN ACUTE AND  
CHRONIC HEART FAILURE 
 
 Mean Uric Acid levels (mg/dl) 
Acute Heart Failure 8.7 
Chronic Heart Failure 7.1 
 
 
 
 Mean uric acid levels were higher in acute decompensated heart 
failure than chronic HF showing the significant association of p value < 0.01. 
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TABLE 13. RISK FACTORS ASSOCIATED WITH HEART FAILURE 
 
Risk Factors Percentage (%) 
Dyslipidemia 53 
Hypertension 47 
Smoking 47 
Diabetes Mellitus 44 
Alcohol 41 
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TABLE 14. DIABETES AND URIC ACID LEVELS 
 
 
Diabetes 
Mellitus 
 
Uric Acid (mg/dl) p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Diabetic 9 3 4 17 11 
<0.01 
Non-diabetic 10 7 19 14 6 
 
 
 
 Serum UA were compared in both diabetic and non-diabetic 
individuals.The correlation had a p value of <0.01, which is significant showing 
that hyperuricemia is associated with impaired glucose tolerance in patients with 
diabetes. 
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TABLE 15. HYPERTENSION AND URIC ACID LEVELS 
 
 
Hypertension 
 
Uric Acid (mg/dl) p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Hypertensive 8 2 6 20 11 
<0.01 
Normotensive 11 8 17 11 6 
 
 
 Serum UA levels were compared in both hypertensive and 
normotensive individuals. The correlation had a p value of <0.01, which is 
significant showing that hyperuricemia is associated with hypertension. 
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TABLE 16. SMOKING AND URIC ACID LEVELS 
 
 
Smoking 
 
Uric Acid (mg/dl) p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Smoker 7 7 13 12 8 
0.330 
Non-smoker 12 3 10 19 9 
 
 
 Serum UA levels were compared in both smokers and non smokers. 
The correlation had a p value of 0.330, which is insignificant. 
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TABLE 17. ALCOHOL AND URIC ACID LEVELS 
 
 
Alcohol 
 
Uric Acid (mg/dl) p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Alcoholic 4 6 13 11 7 
0.121 
Non-alcoholic 15 4 10 20 10 
 
 
 
 Serum UA levels were compared in both alcoholics and non 
alcoholics. The correlation had a p value of 0.121, which is insignificant. 
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TABLE 18. DYSLIPIDEMIA AND URIC ACID LEVELS 
 
 
Dyslipidemia 
 
Uric Acid (mg/dl) p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Present 7 3 14 18 11 
0.204 
Absent 12 7 9 13 6 
 
 
 Serum UA levels were compared in patients with normal lipid profile 
and dyslipidemia. The correlation had a P value of 0.204, which is insignificant. 
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TABLE 19. CORRELATION OF QRS DURATION (ECG) TO  
URIC ACID LEVELS 
 
QRS 
Duration 
(msec) 
Uric Acid (mg/dl) 
p value ≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
> 120 0 0 4 11 9 
<0.001 
< 120 19 10 19 20 8 
 
 
 
 In the study, serum uric acid levels were compared with QRS duration 
of >120 msec and < 120 msec. All patients (100%) with QRS > 120 msec had 
elevated UA levels. The correlation had a p value < 0.001 which is significant. 
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Chart 19. Correlation of QRS duration to Uric Acid 
levels
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TABLE 20. CORRELATION OF REQUIREMENT OF INOTROPES TO 
URIC ACID LEVELS 
 
Inotropes 
Uric Acid (mg/dl) 
p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Required 0 0 1 15 13 
< 0.001 
Not Required 19 10 22 16 4 
 
 
 
 
 In the study, serum uric acid levels were compared with patients who 
required inotropic supports and those who do not. All patients (100%) who 
required inotropes had elevated UA levels. The correlation had a p value < 0.001 
which is significant. 
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TABLE 21. CORRELATION OF RE-HOSPITALIZATION TO  
URIC ACID LEVELS 
 
Re-
hospitalization 
Uric Acid (mg/dl) 
p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Yes 0 0 0 8 5 
<0.003 
No 19 10 23 23 12 
 
 
 
  In the study, serum uric acid levels were compared with patients with 
rehospitalisation rates within one month. All patients (100%) who were 
rehospitalised had elevated UA levels. The correlation had a p value < 0.003 which 
is significant. 
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TABLE 22. CORRELATION OF MORTALITY TO URIC ACID LEVELS 
Mortality 
Uric Acid (mg/dl) 
p value 
≤6.0 6.1-7.0 7.1-8.0 8.1-9.0 >9.0 
Yes 0 0 0 6 7 
< 0.001 
No 19 10 23 25 10 
 
 
  In the study, serum uric acid levels were compared with 30 day 
mortality rate. All patients (100%) who died within one month had elevated UA 
levels. The correlation had a p value < 0.001 which is significant. 
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TABLE 23. COMPARISON OF FEATURES BETWEEN 
HYPERURICEMIA AND NORMOURICEMIA 
Factors Hyperuricemia Normouricemia 
Age (Mean) 49.88 57.21 
Sex (Male %) 55.26 83.33 
LV Ejection Fraction (%) 36.12 49.58 
Diabetes (%) 44.73 41.66 
Hypertension (%) 50 37.5 
Alcohol (%) 44.73 29.16 
Smoking (%) 47.36 45.83 
Dyslipidemia (%) 59.21 33.33 
Acute heart failure (%) 44.73 4.16 
Chronic heart failure (%) 55.26 95.83 
QRS duration (Mean) 31.57 0 
Inotropes required (%) 38.15 0 
Re-hospitalization at 30 days (%) 17.1 0 
Mortality at 30 days (%) 17.1 0 
 
 Mort 30(%)
Re-hos 30(%)
Inotropes(%)
QRS (Mean)
Chr. HF (%)
Acu. HF (%)
Dyslp (%)
Smk (%)
Alc (%)
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Sex (Male%)
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DISCUSSION 
  
DISCUSSION 
 
  Natriuretic peptides have been the established biomarkers for the risk 
stratification of patients with heart failure. Previous studies show that serum uric 
acid may also function as a prognostic risk marker in HF patients. BNP increases 
as an adaptive response due to increased ventricular filling pressures, whereas uric 
acid levels are increased in HF as a maladaptive response of increased xanthine 
oxidase activity reflecting increased vascular tone and impaired cardiac 
contractility. In this study, the diagnostic and prognostic implications of serum UA 
have been studied in a population comprising 100 patients, who were admitted 
with symptoms and signs of heart failure syndromes. These patients were assessed 
clinically on admission and serum UA measured within 6 hours of admission, 
followed by laboratory and echocardiographic evaluation. 
 
  This study shows that hyperuricemia is found in majority (73%) of   
heart failure patients with increased prevalence in females compared to males 
which is in concurrence with the research studies by Michelle and Uzma et.al in 
2009. Serum uric acid levels are increased markedly in acute decompensation than 
chronic heart failure. Pascual and figal in 2007 shows that hyperuricemia is more 
common in acute heart failure syndromes than chronic state and majority of the 
patients with hyperuricemia in acute decompensation shows severe clinical 
impairment. Increased uric acid levels in acute HF indicates increased oxidative 
stress and xanthine oxidase activity causing adverse left ventricular remodeling. 
Endothelial dysfunction and hypoxia causes exaggerated xanthine oxidase activity 
producing hyperuricemia in heart failure, which is further augmented by the 
impaired kidney function and use of diuretics in heart failure. 
 
  Left ventricular ejection fraction and NYHA functional class were 
taken as the markers for the severity of heart failure. The study shows that in 
patients with decreased ejection fraction, all the patients (100%) had significant 
rise in serum UA. As the ejection fraction increased, the number of patients with 
elevated serum uric acid levels proportionately decreased (0% in patients with 
EF>50). This association holds good with a p value of <0.01. Thus this study 
shows that elevated uric acid levels had negative correlation with ejection fraction 
proving that progressive hyperuricemia indicates cardiac dysfunction in heart 
failure. 
  The severity of heart failure was compared with the severity of uric 
acid rise, which showed progressive decrease in ejection fraction with increasing 
uric acid values. This association was statistically significant. The mean uric acid 
values also increased with decreasing ejection fraction. The mean ejection fraction 
in patients with hyperuricemia and normal uric acid levels are 36% and 49% 
respectively. Hence, serum uric levels can be used as a qualitative marker for 
assessing the severity of heart failure. These results were confirmative of the 
research done by Pinelli and Hiroshi et. al in 2007. 
 
  The serum UA levels were compared with various grades of NYHA 
functional class in HF. In patients with grade III and IV NYHA, majority had 
significant rise in serum UA. As the NYHA functional class increases, the number 
of patients with elevated serum uric acid levels proportionately increases. There 
was a progressive rise of serum UA levels from grade I to grade IV NYHA 
functional class in HF patients. This association holds good with a p value of 
<0.01. Thus this study shows that elevated uric acid levels had positive correlation 
with NYHA functional class proving that hyperuricemia indicates progression of 
the disease in heart failure which is similar to the studies done by Domingo. et. al 
in 2007 and Murtaza. et. al in 2009. 
 
  Risk factors associated with heart failure were diabetes, hypertension, 
smoking, alcohol and dyslipidemia. All these risk factors were individually studied 
and compared with normouricemic and hyperuricemic group of patients. Studies of 
Uzma et. al in 2009 and Yoo et al.in 2005 have demonstrated that serum uric acid 
concentration was shown to independently correlate with hypertension. In our 
study there was significant association between hyperuricemia and hypertension as 
evident by p value < 0.01. Hyperuricemia per se stimulate vascular remodeling and 
smooth musle proliferation causing hypertension. Thus this study shows that 
hyperuricemia is independently linked with hypertension irrespective of the 
etiology of heart failure. 
 
  Studies by Yoo et. al in 2005 and Becker and Jolly in 2006 showed 
that hyperuricemia was clearly related to hyperglycemia. In our present study we 
found there was a significant correlation between hyperuricemia and diabetes with 
p value < 0.01. Insulin resistance, hyperinsulinemia and tissue wasting in diabetes 
accelerated the catabolism of purines leading to hyperuricemia. Cappuccio and 
colleagues showed that hyperuricemia is associated with increased renal sodium 
reabsorption thus linking increased uric acid levels with hypertension and 
hyperinsulinemia. Thus this study shows that increased uric acid levels are 
associated with diabetes significantly irrespective of the etiology of heart failure. 
 
  Studies done by Uzma et.al.in 2009 shows that hyperuricemia was not 
independently associated with hyperlipidemia. This study also shows similar 
results that hyperuricemia had no correlation with hyperlipidemia with a p value of  
0.204. Further alcohol use and smoking also had no correlation with hyperuricemia 
with p value of 0.330 and 0.121 respectively. 
  The relevant hemodynamic characteristics of normouricemic and 
hyperuricemic heart failure patients were compared. These include QRS duration 
in ECG, and requirement of ionotropes. It was found that patients with elevated 
uric acid levels were associated with impaired haemodynamics in the form of 
increased incidence of hypotension. Hyperuricemic patients had wider QRS 
complexes suggesting increased atrio ventricular dysynchrony and were associated 
with increased requirement for ionotropes during the initial management. The 
association was statistically significant with the p value < 0.001 which is in 
concurrence with the results of Anker and Stefan et.al in 2009. 
 
  The prognosis of patients was assessed by means of 30 day mortality 
rate and rehospitalization rates within one month. It was found that patients with 
higher serum uric acid levels were associated with increased rates of 
rehospitalization and increased mortality rate. The association was statistically 
significant with a p value of < 0.001. Adriana and Danielle et. al in 2008 also 
proved the same association. 
 
  From the above findings, it is made clear that elevated uric acid levels 
serves as a clinical marker for the multiple pathological processes in the 
progression of heart failure and reduction in xanthine oxidase activity improves 
cardiac contractility, reduces oxidative stress, limits infarct size, inflammation and 
platelet adhesiveness. All these effects would be protective to patients with heart 
failure and suggests a hypothesis that xanthine oxidase inhibitors may act as novel 
drugs in the management of cardiac failure in future.  
 
  This study had certain limitations. Results could have been more 
accurate by increasing the sample size. The patients were followed up only for 1 
month and by increasing the duration of follow up by 6 months to 1 year would 
have achieved better assessment of differences in the results. 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
CONCLUSION 
  
CONCLUSION 
 
 
  To conclude, the prevalence of hyperuricemia was found to be 
significantly higher in patients with cardiac failure and the severity of UA rise had 
a high correlation to the severity of heart failure. Hyperuricemia is more common 
in acute decompensated heart failure than chronic heart failure patients. Elevated 
serum uric acid levels correlate inversely with ejection fraction suggesting that 
progressive hyperuricemia in cardiac failure indicates deteriorating cardiac 
function. Patients with elevated serum UA levels were associated with poorer 
NYHA functional class proving that hyperuricemia predicts the severity of cardiac 
failure. Hyperuricemic patients were associated with adverse clinical and 
biochemical features compared to normouricemic patients in the form of increased 
QRS duration and inotropic requirements. Serum uric acid levels were increased in 
diabetes and hypertension and had an independent association, irrespective of the 
etiology of heart failure. Patients with higher uric acid levels were associated with 
adverse outcomes and poor prognosis in the form of increased rehospitalization 
rates and 30 day mortality rates. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
  
SUMMARY 
 
 
  The study was initiated in order to determine the prognostic 
significance of serum uric acid levels in heart failure syndromes and its correlation 
with ejection fraction. 
 
  The study was conducted in Coimbatore medical college hospital, 
Coimbatore, which included 100 patients who were admitted with features of heart 
failure. Patients, who satisfied the criteria for inclusion, were subjected to basic 
blood investigations and serum uric acid levels were measured in them. 
Echocardiography was done in all the patients to assess the severity of heart 
failure. The patients were followed up for a period of one month to determine the 
mortality and adverse outcomes. 
 
  Results from the study showed that serum uric acid levels were 
significantly raised in heart failure. Increased serum uric acid levels in heart failure 
correlates negatively with ejection fraction and positivey with NYHA functional 
class, thus predicting the prognosis and severity. Hyperuricemia is independently 
associated with hypertension and diabetes, irrespective of the etiology of cardiac 
failure. Increased serum uric acid levels were also associated with adverse 
outcomes in terms of rehospitalisation rates and mortality. 
  Thus, it is evident from this study that high serum uric acid levels 
could be a strong and valid biomarker of impaired prognosis and mortality in 
patients with cardiac failure, predicting the severity and hemodynamic 
derangements. The measurement of serum uric acid levels is simple and widely 
available at low cost. Hence routine measurement of serum uric acid levels in 
assessing the cardiovascular risks may contribute to the improved ability to stratify 
risk in cardiac failure. 
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ANNEXURES 
 
PROGNOSTIC SIGNIFICANCE OF SERUM URIC ACID LEVELS IN 
CONGESTIVE CARDIAC FAILURE AND ITS CORRELATION WITH                                 
EJECTION FRACTION 
S.No:      Uric  Acid:    mg/dl 
Name :     Occupation: 
Age / Sex:     Address: 
Weight:                                 BMI: 
DOA:      DOD:                                Phone No: 
ETIOLOGICAL DIAGNOSIS : 
Ischaemic heart disease  Rheumatic heart disease   
Congenital heart disease             Others  
RISK FACTORS: 
SHT    Smoking    Dyslipidemia 
DM    Alcohol    Others  
CLINICAL FEATURES:                                       
NYHA Functional class: I /II/ III / IV   SBP: 
Dyspnoea         DBP: 
Edema       Pulse Rate: 
Cough        Apex: 
Chest Pain       JVP: 
Palpitation        Acute / chronic :  
 
ELECTROCARDIOGRAM: 
Ischemic changes     Arrhythmias 
LAE       QRS Duration QRS >120ms 
LVH          QRS < 120ms 
ECHOCARDIOGRAM:     X-RAY CHEST: 
LVEF % :         CTR : 
RWMA        Cardiomegaly 
Valvular Heart Diseases      Pulmonary Edema 
 MS  AS 
 MR  AR 
Others 
TREATMENT:  
 Required Inotropes      
  Yes  No        
PROGNOSIS: 
 Mortality      Rehospitalisation < 30 days 
  < 1 day       Yes 
  1-7 days        No 
  7-30 days       
 
S.N0 
Name 
Age 
Age 
Gr 
Sex UA 
UA 
Gr 
EF 
EF 
Gr 
DM SHT Alcoh Smok Dys Eti A/C NYHA  Mort Reh Ino QRS  
1 ponnusamy 55 5 M 8.9 4 24 4 1 1 1 1 1 1 2 3 1 1 1 1 
2 raju 50 5 M 7.6 3 36 3 1 2 1 1 1 1 2 3 2 2 2 2 
3 lakshmi 54 5 F 8.8 4 43 2 1 1 2 2 1 1 2 3 2 2 2 1 
4 sundaram 57 5 M 9.8 5 28 4 1 1 1 1 1 1 1 4 1 1 1 1 
5 rajamani 44 4 F 9 5 30 3 1 1 2 2 1 1 1 3 2 2 1 1 
6 sabarathnam 76 7 M 6 1 42 2 2 2 2 1 2 1 2 2 2 2 2 2 
7 subramani 44 4 M 7.4 3 44 2 1 2 2 1 2 1 2 3 2 2 2 1 
8 sarasu 36 3 F 8.4 4 32 3 2 2 2 2 2 2 2 3 2 2 1 2 
9 arunachalam 47 4 M 8.2 4 31 3 1 1 1 2 1 1 2 3 2 2 1 1 
10 eswaran 62 6 M 5.9 1 56 1 1 1 2 1 1 3 2 2 2 2 2 2 
11 saraswat 80 8 F 9 5 22 4 1 1 2 2 1 1 2 3 1 2 1 1 
12 murugan 55 5 M 5.4 1 46 2 2 2 2 2 2 1 2 3 2 2 2 2 
13 kaliammal 27 2 F 7.8 3 34 3 2 2 2 2 2 2 1 3 2 2 2 2 
14 rajesh 32 3 M 8.8 4 29 4 2 2 2 1 2 2 1 4 2 2 1 2 
15 Parvathi 56 5 F 8.1 4 44 2 2 1 2 2 2 4 2 3 2 2 2 2 
16 rajan 65 6 M 7.8 3 36 3 2 2 1 1 1 1 2 3 2 2 2 2 
17 amudha 28 2 F 9.1 5 34 3 2 2 2 2 2 2 1 4 2 2 2 2 
18 madesh 48 4 M 9.4 5 28 4 1 1 1 1 1 1 1 4 2 1 1 1 
19 arumugam 36 3 M 7.9 3 36 3 2 2 2 1 2 2 2 3 2 2 2 2 
20 selvi 28 2 F 9.2 5 30 3 2 2 2 2 2 2 1 4 2 2 1 2 
21 Tamilselvan 34 3 M 8.1 4 32 3 2 2 1 1 2 2 1 4 2 2 2 2 
22 Jasmine 30 3 F 8.6 4 36 3 2 2 2 2 2 2 2 3 2 2 2 2 
23 akbar ali 67 6 M 6 1 58 1 1 1 2 1 1 3 2 4 2 2 2 2 
24 Jeyammal 62 6 F 8.8 4 31 3 1 1 2 2 1 1 1 4 1 1 1 2 
25 nagaraj 65 6 M 9.4 5 36 3 1 1 1 1 1 1 1 4 1 1 2 1 
26 sundari 48 4 F 7.8 3 42 2 2 2 2 2 1 1 2 3 2 2 2 1 
27 samsudeen 63 6 M 7.4 3 46 2 2 2 1 1 2 4 2 3 2 2 2 2 
28 lakshmi 39 3 F 8.8 4 32 3 2 2 2 2 2 2 1 4 2 1 1 2 
MASTER CHART 
29 kuppusamy 74 7 M 6.8 2 45 2 2 2 2 1 1 1 2 2 2 2 2 2 
30 rukmani 50 5 F 7 2 42 2 2 2 2 2 1 1 2 3 2 2 2 2 
31 shanmugam 75 7 M 5.8 1 46 2 2 2 1 1 2 1 2 2 2 2 2 2 
32 valli 32 3 F 8.6 4 32 3 2 2 2 2 2 2 1 3 2 2 1 2 
33 jayraj 56 5 M 8.2 4 42 2 1 1 1 1 1 4 2 3 2 2 2 2 
34 Ramani 52 5 F 7.5 3 46 2 2 2 2 2 2 4 2 3 2 2 2 2 
35 jaykumar 37 3 M 9.2 5 27 4 2 2 1 1 2 2 1 4 2 2 1 2 
36 sukumar 50 5 M 9 5 32 3 1 1 1 1 1 1 1 4 1 1 1 1 
37 kanagavalli 56 5 F 8.1 4 41 2 1 1 2 2 1 1 2 3 2 1 2 1 
38 ramasamy 72 7 M 7.2 3 46 2 2 2 1 1 1 1 2 3 2 2 2 1 
39 saraswathi 60 6 F 7.6 3 42 2 2 1 2 2 2 4 2 3 2 2 2 2 
40 kumar 34 3 M 8.6 4 32 3 2 2 1 1 2 2 1 4 2 2 1 2 
41 mariammal 62 6 F 6.2 2 46 2 2 2 2 2 2 4 2 3 2 2 2 2 
42 rathnam 64 6 M 7.6 3 44 2 2 2 1 1 1 1 2 3 2 2 2 2 
43 palanisamy 62 6 M 6.8 2 37 3 1 2 1 1 2 1 2 3 2 2 2 2 
44 saravanan 48 4 M 5.9 1 48 2 2 2 2 1 2 1 2 2 2 2 2 2 
45 jayakumari 53 5 F 9.2 5 29 4 1 1 2 2 1 1 2 3 1 2 1 1 
46 kadhir 40 4 M 6.4 2 48 2 2 2 1 1 2 1 2 2 2 2 2 2 
47 rasamma 80 8 F 7.8 3 38 3 2 1 2 2 1 1 2 3 2 2 2 2 
48 velu 30 3 M 9.1 5 28 4 2 2 2 1 2 2 1 4 2 2 1 2 
49 kadhiresan 35 3 M 8.8 4 34 3 2 2 2 1 2 2 1 4 2 2 2 2 
50 rakkayi 56 5 F 7.2 3 45 2 2 2 2 2 2 1 2 3 2 2 2 2 
51 Muthumani 45 4 M 8.2 4 34 3 1 1 1 1 1 1 2 3 2 2 2 2 
52 latha 56 5 F 5.6 1 47 2 2 2 2 2 2 1 2 2 2 2 2 2 
53 Manikandan 32 3 M 9 5 35 3 2 2 2 2 2 2 1 4 2 2 2 2 
54 Sundareswari 60 6 F 8 4 42 2 1 1 2 2 1 1 2 3 2 2 2 2 
55 Rajamanikam 52 5 M 9.4 5 27 4 1 1 1 1 1 1 1 4 1 2 1 1 
56 Boomithai 45 4 F 5.4 1 48 2 2 2 2 2 2 1 2 2 2 2 2 2 
57 Sachidanandam 55 5 M 7.6 3 36 3 2 2 2 2 2 2 1 4 2 2 2 2 
58 Vijay 32 3 M 8.4 4 34 3 1 1 2 2 1 1 2 3 2 2 2 2 
59 Rajathi 33 3 F 8.4 4 36 3 1 1 1 1 1 1 1 4 1 2 1 1 
60 Kuppusamy 68 6 M 7.2 3 42 2 2 2 1 1 1 1 2 3 2 2 2 2 
61 Rangaraj 65 6 M 5.4 1 46 2 2 2 2 2 2 1 2 2 2 2 2 2 
62 Lakshmanan 45 4 M 5.9 1 54 1 1 1 2 2 1 3 2 1 2 2 2 2 
63 Raja 44 4 M 5.6 1 48 2 2 2 2 2 1 4 1 2 2 2 2 2 
64 Munusamy 75 7 M 5.8 1 54 1 1 1 2 1 1 3 2 1 2 2 2 2 
65 Kanaga 60 4 F 8.6 4 34 3 1 1 2 2 1 1 1 4 1 2 1 1 
66 Ganasan 55 5 M 7 2 46 2 2 2 1 1 2 1 2 2 2 2 2 2 
67 Malliga 60 6 F 8.8 4 39 3 1 1 2 2 1 1 2 3 2 2 2 1 
68 madesh 45 4 M 5.4 1 52 1 1 1 2 2 2 3 2 1 2 2 2 2 
69 Asairani 48 4 F 9.3 5 32 3 1 1 2 2 1 2 1 3 2 2 1 2 
70 Sanjeevan 60 6 M 6 1 56 1 1 1 1 2 1 3 2 1 2 2 2 2 
71 Booma 47 4 F 9.2 5 32 3 1 1 2 2 1 1 1 4 2 2 1 1 
72 Nagalaxmi 55 5 F 8.1 4 42 2 1 1 2 2 1 1 2 3 2 2 2 1 
73 Udayakumar 53 5 M 6.6 2 48 2 2 2 1 1 2 4 2 3 2 2 2 2 
74 Kumari 44 4 F 8.1 4 32 3 2 1 2 2 1 2 1 4 2 2 1 2 
75 Surendran 57 5 M 5.4 1 52 1 2 2 1 1 2 1 2 2 2 2 2 2 
76 Krishnaveni 60 6 F 7.5 3 42 2 2 2 2 2 1 1 2 3 2 2 2 2 
77 Marudhu 50 5 M 8.6 4 34 3 1 1 1 1 1 1 1 4 1 1 2 1 
78 Malleswari 60 6 F 5.2 1 54 1 1 1 2 2 2 3 2 3 2 2 2 2 
79 Dandapani 40 4 M 7 2 46 2 1 1 1 1 1 1 2 3 2 2 2 2 
80 Kathiresan 40 4 M 5.8 1 48 2 2 2 1 2 2 1 2 2 2 2 2 2 
81 Krishnan 80 8 M 7.4 3 33 3 2 2 1 1 1 1 2 3 2 2 1 2 
82 Anandhi 36 3 F 8 4 32 3 2 2 2 2 2 2 1 4 2 1 1 2 
83 Arivalagan 44 4 M 8.6 4 32 3 1 1 1 1 1 1 1 4 2 1 1 1 
84 Arokiamary 28 2 F 8.8 4 28 4 2 2 2 2 2 2 1 4 2 2 1 2 
85 Venkatachalam 64 6 M 6.8 2 46 2 1 1 1 1 2 1 2 3 2 2 2 2 
86 Palani 70 7 M 7 3 48 2 2 1 1 1 2 1 2 3 2 2 2 2 
87 Muthusamy 61 6 M 5.8 1 58 1 1 1 2 2 1 3 2 3 2 2 2 2 
88 Devan 48 4 M 7.4 3 42 2 2 1 1 1 1 1 2 3 2 2 2 2 
89 Pughalendhi 62 6 M 8.8 4 34 3 1 1 1 1 1 1 1 4 1 2 2 1 
90 Das 55 5 M 7.4 3 41 2 1 1 1 1 1 1 2 3 2 2 2 2 
91 Asokan 33 3 M 9 5 32 3 2 2 2 2 2 2 1 4 2 1 2 2 
92 Sakthi 46 4 F 5.4 1 42 2 1 2 2 2 2 1 2 1 2 2 2 2 
93 Sharma 60 6 M 9 5 28 4 1 1 1 1 1 1 1 4 1 2 1 2 
94 Suganthi 35 3 F 8.2 4 36 3 2 2 2 2 2 2 1 3 2 1 2 2 
95 Karuppasamy 65 6 M 8.6 4 41 2 1 1 1 1 1 1 2 3 2 2 2 2 
96 Sadagopan 47 4 M 7.6 3 44 2 2 2 1 1 1 1 2 3 2 2 2 1 
97 Subramani 73 7 M 7.4 3 36 3 1 1 1 2 1 1 2 3 2 2 2 2 
98 Veeradas 50 5 M 7.2 3 42 2 2 2 1 2 1 1 2 2 2 2 2 2 
99 Jaffer 60 6 M 6.2 2 48 2 2 2 2 2 2 1 2 1 2 2 2 2 
100 Veni 40 4 F 8 4 32 3 2 1 2 2 2 2 1 3 2 2 1 2 
KEY TO MASTER CHART 
 
S.No    -   Serial number 
Age Gr  -   Age Grade 
UA   -   Uric Acid 
UA Gr -   Uric Acid Grade 
EF   -   Ejection Fraction 
EF Gr  -   Ejection Fraction Grade 
DM  -   Diabetes Mellitus 
SHT  -   Systemic Hypertension 
Alcoh  -    Alcohol Intake 
Smok  -    Smoker 
Dys  -    Dyslipidemia 
A  -    Acute (1) 
C  -    Chronic (2) 
NYHA -    New York Heart Association Functional class for heart failure 
Ino  -    Inotropes required 
Reh  -    Rehospitalisation within 30 days 
QRS   -    QRS Duration > 120 msec 
1  -    Yes 
2  -    No 
M  -     Male 
F  -     Female 
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